Introduction {#s1}
============

Sequences resulting from retrotransposition constitute more than half of the human genome and are considered to be major change agents in eukaryotic genome evolution ([@bib50]). L1 retrotransposons have been particularly active in mammals ([@bib30]), comprising \~20% of the human genome ([@bib59]); somatic retrotransposition has been widely implicated in cancer progression ([@bib60]; [@bib98]) and may even play a role in neural development ([@bib73]). Despite the magnitude of their contributions to mammalian genomes, L1 genes are modest in size. A full-length L1 transcript is \~6 knt long and functions as a bicistronic mRNA that encodes two polypeptides, ORF1p and ORF2p ([@bib79]), which respectively comprise a homotrimeric RNA binding protein with nucleic acid chaperone activity ([@bib65]) and a multifunctional protein with endonuclease and reverse transcriptase activities ([@bib67]; [@bib29]). Recently, a putative primate-specific third ORF, named *ORF0*, has been identified on the Crick strand of the L1 gene; this ORF encodes a 71 amino acid peptide and may generate insertion-site-dependent ORFs via splicing ([@bib22]). ORF1p and ORF2p are thought to interact preferentially with the L1 RNA from which they were translated (in cis), forming a ribonucleoprotein (RNP) ([@bib57]; [@bib96]) considered to be the canonical direct intermediate of retrotransposition ([@bib43]; [@bib56]; [@bib66]; [@bib57]; [@bib25]). L1 RNPs also require host factors to complete their lifecycle ([@bib91]; [@bib82]; [@bib21]; [@bib96]) and, consistent with a fundamentally parasitic relationship ([@bib8]), the host has responded by evolving mechanisms that suppress retrotransposition ([@bib34]; [@bib4]; [@bib33]; [@bib75]). It follows that as the host and the parasite compete, L1 expression is likely to produce a multiplicity of RNP forms engaged in discrete stages of retrotransposition, suppression, or degradation.

Although L1 DNA sequences are modestly sized compared to typical human genes, L1 intermediates are nevertheless RNPs with a substantially sized RNA component; e.g. larger than the \~5 knt 28S rRNA ([@bib32]) and approximately three to four times the size of a 'typical' mRNA transcript ([@bib59]; [@bib90]). Therefore, it is likely that many proteins within L1 RNPs form interactions influenced directly and indirectly by physical contacts with the L1 RNA. We previously reported that L1 RNA comprised an estimated \~25% of mapped RNA sequencing reads in ORF2p-3xFLAG affinity captured fractions ([@bib96]). We also observed that the retention of ORF1p and UPF1 within affinity captured L1 RNPs was reduced by treatment with RNases ([@bib96]). In the same study we observed that two populations of ORF2p-associated proteins could be separated by split-tandem affinity capture (ORF2p followed by ORF1p), a two-dimensional affinity enrichment procedure ([@bib16]; [@bib96]). Initial characterization of these two L1 populations by western blotting suggested that discrete L1 populations were likely primed for function in different stages of the lifecycle. We therefore expected additional uncharacterized complexity in the spectrum of L1-associated complexes present in our affinity enriched fractions.

In this study, we have used quantitative mass spectrometry (MS) to investigate the proteomic characteristics of endogenously assembled ectopic L1-derived macromolecules present in an assortment of affinity-enriched fractions. We revisited RNase treatment and split-tandem affinity capture approaches and complemented them with RNA sequencing, enzymatic analysis, and in-cell localization of ORF proteins by immunofluorescence microscopy (see also the companion manuscript by [@bib71]). We additionally explored proteomes associated with catalytically-inactivated ORF2p point mutants and monitored the rates of protein exchange from L1 macromolecules in vitro. Taken together, our data support the existence of a variety of putative L1-related protein complexes.

Results {#s2}
=======

Affinity proteomic experiments conducted in this study use quantitative MS based upon metabolic labeling ([@bib76]). Two main experimental designs (and modifications thereof) facilitating quantitative cross-sample comparisons have been used: SILAC ([@bib78]; [@bib101]) and I-DIRT ([@bib92]; [@bib96]). In these approaches, cells are grown for several doublings in media containing amino acids composed either of naturally-occurring 'light\' isotopes or biologically identical \'heavy\' isotopes (e.g. ^13^C, ^15^N lysine and arginine), such that the proteomes are thoroughly labeled. Protein fractions derived from the differently labeled cell populations, obtained e.g. before and after experimental manipulations are applied, are mixed and the relative differences in proteins contributed by each fraction are precisely measured by mass spectrometry. In addition to the above cited studies, these approaches have been adapted to numerous biological questions using a variety of analytical frameworks e.g. ([@bib14]; [@bib64]; [@bib97]; [@bib77]; [@bib47]; [@bib31]). Because it is challenging to speculate on the potential physiological roles of protein interactions that form after extraction from the cell, we often use I-DIRT, which allows the discrimination of protein-protein interactions formed in-cell from those occurring post-extraction. Our prior affinity proteomic study, based on I-DIRT, identified 37 putative *in vivo* interactors ([@bib96]), described in [Table 1](#table1){ref-type="table"}. In this study we primarily analyze the behaviors of these 'I-DIRT significant' L1 interactors, in order to determine their molecular associations and ascertain the variety of distinctive macromolecular complexes formed in-cell that copurify with affinity-tagged ORF2p. The complete lists of proteins detected in each experiment are presented in the supplementary information (see [Supplementary file 1](#supp1){ref-type="supplementary-material"}). We have represented any ambiguous protein group, which occurs when the same peptides identify a group of homologous protein sequences, with a single, consistently applied gene symbol and a superscript \'a\' in all figures. [Supplementary file 1](#supp1){ref-type="supplementary-material"} contains the references to other proteins explaining the presence of the same peptides. For example, RPS27A, (ubiquitin) UBB, UBC, and (ribosomal Protein L40) UBA52 can be explained by common ubiquitin peptides shared by these genes. RPS27A-specific peptides were not identified in this study, but we retained the nomenclature for consistency with our previous work; HSPA1A is reported in this study, but cannot be distinguished from the essentially identical protein product of HSPA1B.
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###### Putative L1 interactors: Through a series of affinity capture experiments (co-IP) using I-DIRT, we characterized a set of putative host-encoded L1 interactors ([@bib96]). 

The proteins observed were associated with both ORF1p and ORF2p (highlighted in blue), only in association with ORF2p (highlighted in magenta), or only in association with ORF1p (no highlight). The two highlighted populations are the central focus of this study.

  Gene symbol   Uniprot symbol   Protein                                                                **co-IP with**
  ------------- ---------------- ---------------------------------------------------------------------- ----------------
  L1RE1         Q9UN81           ORF1p                                                                  ORF1/2
  N/A           O00370           ORF2p                                                                  ORF1/2
  MOV10         Q9HCE1           Putative helicase MOV-10                                               ORF1/2
  PABPC1        P11940           Polyadenylate-binding protein 1                                        ORF1/2
  PABPC4        Q13310           Polyadenylate-binding protein 4                                        ORF1/2
  UPF1          Q92900           Regulator of nonsense transcripts 1                                    ORF1/2
  ZCCHC3        Q9NUD5           Zinc finger CCHC domain-containing protein 3                           ORF1/2
  FKBP4         Q02790           Peptidyl-prolyl cis-trans isomerase FKBP4                              ORF2
  HAX1          O00165           HCLS1-associated protein X-1                                           ORF2
  HMCES         Q96FZ2           Embryonic stem cell-specific 5-hydroxymethylcytosine-binding protein   ORF2
  HSP90AA1      P07900           Heat shock protein HSP 90-alpha                                        ORF2
  HSP90AB1      P08238           Heat shock protein HSP 90-beta                                         ORF2
  HSPA1A        P0DMV8           Heat shock 70 kDa protein 1A                                           ORF2
  HSPA8         P11142           Heat shock cognate 71 kDa protein                                      ORF2
  IPO7          O95373           Importin-7                                                             ORF2
  NAP1L1        P55209           Nucleosome assembly protein 1-like 1                                   ORF2
  NAP1L4        Q99733           Nucleosome assembly protein 1-like 4                                   ORF2
  PARP1         P09874           Poly \[ADP-ribose\] polymerase 1                                       ORF2
  PCNA          P12004           Proliferating cell nuclear antigen                                     ORF2
  PURA          Q00577           Transcriptional activator protein Pur-alpha                            ORF2
  PURB          Q96QR8           Transcriptional activator protein Pur-beta                             ORF2
  RPS27A        P62979           Ubiquitin-40S ribosomal protein S27a                                   ORF2
  TIMM13        Q9Y5L4           Mitochondrial import inner membrane translocase subunit Tim13          ORF2
  TOP1          P11387           DNA topoisomerase 1                                                    ORF2
  TOMM40        O96008           Mitochondrial import receptor subunit TOM40 homolog                    ORF2
  TUBB          P07437           Tubulin beta chain                                                     ORF2
  TUBB4B        P68371           Tubulin beta-4B chain                                                  ORF2
  YME1L         Q96TA2           ATP-dependent zinc metalloprotease YME1L1                              ORF2
  CORO1B        Q9BR76           Coronin-1B                                                             ORF1
  DDX6          P26196           Probable ATP-dependent RNA helicase DDX6                               ORF1
  ERAL1         O75616           GTPase Era, mitochondrial                                              ORF1
  HIST1H2BO     P23527           Histone H2B type 1-O                                                   ORF1
  LARP7         Q4G0J3           La-related protein 7                                                   ORF1
  MEPCE         Q7L2J0           7SK snRNA methylphosphate capping enzyme                               ORF1
  PABPC4L       P0CB38           Polyadenylate-binding protein 4-like                                   ORF1
  TROVE2        P10155           60 kDa SS-A/Ro ribonucleoprotein                                       ORF1
  YARS2         Q9Y2Z4           Tyrosine\--tRNA ligase, mitochondrial                                  ORF1

Except where noted otherwise, the presented experiments were conducted in suspension-cultured HEK-293T~LD~ cells, using a synthetic L1 construct - *ORFeus*-HS - driving the expression 3xFLAG-tagged L1 (*ORF1; ORF2::3xFLAG*; 3'-UTR) from a tetracycline inducible minimal-CMV promoter, harbored on a mammalian episome (pLD401 ([@bib96]; [@bib3]; [@bib21])). All L1-related macromolecules described in this study were obtained by affinity capture of ORF2p-3xFLAG before further experimental manipulations were applied. We consider macromolecules containing L1 RNA (L1 RNPs, discussed throughout) and/or an L1 cDNA (i.e. L1 coding potential) to be L1s, as are their ectopic plasmid-borne and endogenous gDNA counterparts, reflecting the complexity and diversity of L1 forms arising from its lifecycle. In an effort to characterize this complexity, we have carried out RNA sequencing and enzymatic activity analyses on several affinity captured fractions, complementing the proteomic analyses.

RNase-sensitivity exhibited by components of affinity captured L1 RNPs {#s2-1}
----------------------------------------------------------------------

[Figure 1](#fig1){ref-type="fig"} (panels A-C) illustrates the approach and displays the findings of our assay designed to reveal which proteins depend upon the presence of intact L1 RNA for retention within the obtained L1 RNPs. Briefly, metabolically-labeled affinity captured L1s were treated either with a mixture of RNases A and T1 --- thus releasing proteins that require intact RNA to remain linked to ORF2p and the affinity medium --- or BSA, as an inert control. After removing the fractions released by the RNase or BSA treatments, the proteins remaining on the affinity media were eluted with lithium dodecyl sulfate (LDS), mixed together, and then analyzed by MS. Proteins released, and so depleted, by RNase treatment were thus found to be more abundant in the BSA-treated control. The results obtained corroborate and extend our previous findings: ORF1p and UPF1 exhibited RNase-sensitivity ([@bib96]). We also observed that ZCCHC3 and MOV10 exhibited RNase-sensitivity to a level similar to ORF1p. The remaining I-DIRT significant proteins were RNase-resistant in this assay. With the exception of the PABPC1/4 proteins (and ORF2p itself, see Discussion), the I-DIRT significant proteins (colored nodes, [Figure 1C](#fig1){ref-type="fig"}) that were resistant to RNase treatment (nearest the origin of the graph) classify ontologically as nuclear proteins (GO:0005634, p ≈ 3 × 10^−4^, see Materials and methods). These same proteins were previously observed as specific L1 interactors in I-DIRT experiments targeting ORF2p but not in those targeting ORF1p; in contrast, the proteins that demonstrated RNase-sensitivity: ORF1, MOV10, ZCCHC3, and UPF1 were observed in both ORF1p and ORF2p I-DIRT experiments ([Table 1](#table1){ref-type="table"}). Stated another way, the proteins released upon treating an affinity captured ORF2p fraction with RNases are among those that can also be obtained when affinity capturing ORF1p directly, while those that are RNase-resistant are not ORF1p interactors ([@bib96]). The ORF1p-linked, I-DIRT significant, RNase-sensitive proteins were too few to obtain a high confidence assessment of ontological enrichment; but, when combined with the remaining proteins exhibiting sensitivity to RNase treatment (black nodes, [Figure 1C](#fig1){ref-type="fig"}), they together classified as \'RNA binding\' (GO:0003723, p ≈ 1 × 10^−11^). This analysis also revealed a statistically significant overrepresentation of genes associated with the exon junction complex (EJC, GO: 0035145, p ≈ 1 × 10^−6^, discussed below). Hence, the overlapping portion of the ORF1p- and ORF2p-associated interactomes appeared to depend upon intact L1 RNA. Host-encoded proteins segregated into groups that responded differentially to RNase treatment, with a substantial population of RNase-resistant interactors linked to both ORF2p and the nucleus. This observation led to the hypothesis that our ORF2p-3xFLAG affinity captured L1s constitute a composite purification of at least, but not limited to, (1) a population of L1-RNA-dependent, ORF1p/ORF2p-containing L1 RNPs, and (2) an ORF1p-independent nuclear population associated with ORF2p.

![RNase sensitivity and split-tandem affinity capture of L1 ORF2p RNPs.\
(**A**) On-bead RNase-sensitivity assay: L1 complexes were affinity captured by ORF2p-3xFLAG. The magnetic media were then treated with a solution containing either a mixture of RNases A and T1 or BSA. After treatment, the supernatants were removed and the remaining bound material was released with LDS. Proteins requiring intact RNA to maintain stable interactions with immobilized ORF2p were released from the RNase-treated medium, while the BSA-treated sample controlled for the spontaneous release of proteins from the medium. Representative SDS-PAGE/Coomassie blue stained gel lanes are shown for each fraction. (**B**) The experiments described above were carried out in duplicate, once with light isotopically labeled cells (**L**) and once with heavy isotopically labeled cells (**H**), resulting in four label-swapped, SILAC duplicates (one light set and one heavy set). The four fractions were cross-mixed and the differential protein retention upon the affinity medium during the treatments (BSA vs. RNase) was assessed by quantitative MS. (**C**) Results from the RNase-sensitivity assay graphed as the fraction of each detected protein present in the BSA-treated sample (RNase-sensitive proteins are *more* present in the BSA treated sample), normalized such that proteins that did not change upon treatment with RNases are centered at the origin. A cut-off of p=10^−3^ for RNase-sensitivity is indicated by a light gray circle; proteins that are RNase-sensitive with a statistical significance of p\<10^−3^ are outside the circle. Proteins previously ranked significant by I-DIRT analysis ([Table 1](#table1){ref-type="table"}) are labeled and displayed in blue or magenta (as indicated); black nodes were RNase-sensitive but not significant by I-DIRT; gray, unlabeled nodes were neither RNase-sensitive nor significant by I-DIRT. (**D**) *Split-tandem affinity capture*: L1 complexes were affinity captured by ORF2p-3xFLAG. After native elution with 3xFLAG peptide, this fraction was depleted of ORF1p-containing complexes using an α-ORF1 conjugated magnetic medium, resulting in a supernatant fraction depleted of ORF1p-containing complexes. The α-ORF1 bound material was then released with LDS, yielding an elution fraction enriched for ORF1p-containing complexes. Representative SDS-PAGE/Coomassie blue stained results for each fraction are shown. (**E**) SILAC duplicates, two supernatants and two elutions, were cross-mixed to enable an assessment of the relative protein content of each fraction by quantitative MS. (**F**) The results from split-tandem affinity capture graphed as the fraction of each protein observed in the elution sample. In order to easily visualize the relative degree of co-partitioning of constituent proteins with ORF1p, these data were normalized, setting the fraction of ORF1p in the elution to 1. Proteins which were previously ranked significant by I-DIRT analysis are labeled and displayed in blue or magenta (as indicated); gray, unlabeled nodes were not found to be significant by I-DIRT. MOV10 is marked with a dagger because in one replicate of this experiment it was detected by a single unique peptide, whereas we have enforced a minimum of two peptides (see Materials and methods) for all other proteins, throughout all other proteomic analyses presented here.](elife-30094-fig1){#fig1}

While effects of PABPC1, MOV10, and UPF1 on L1 activity have been described ([@bib4]; [@bib96]; [@bib21]), effects of ZCCHC3 on L1 remained uncharacterized. ZCCHC3 is an RNA-binding protein associated with poly(A)+ RNAs ([@bib17]) but otherwise little is known concerning its functions. Notably, in a genome-wide screen, small interfering (si)RNA knockdown of ZCCHC3 was observed to increase the infectivity of the Hepatitis C, a positive sense RNA virus ([@bib61]); and ZCCHC3 was observed to copurify with affinity captured HIV, a retrovirus, at a very high SILAC ratio (\>10), supporting the specificity of this interaction ([@bib27]). We therefore explored the effects on L1 mobility both of over-expression and siRNA knockdown of ZCCHC3. Over-expression of ZCCHC3 reduced L1 retrotransposition to \~10% that observed in the control, consistent with a negative regulatory role for ZCCHC3 in the L1 lifecycle; small interfering RNA (siRNA) knockdown of ZCCHC3 induced a modest increase in retrotransposition compared to a scrambled control siRNA (\~1.9x ± 0.1; [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Moreover, although not among our I-DIRT hits (see Discussion), the presence of EJC components (MAGOH, RBM8A, EIF4A3, UPF1) among the RNase-sensitive fraction of proteins intrigued us, given that L1 genes are intronless. We speculated that L1s may use EJCs to enhance nuclear export, evade degradation by host defenses, and/or aggregate with mRNPs within cytoplasmic granules. For this reason we carried out a series of siRNA knockdowns of these EJC components and other physically or functionally related proteins found in the affinity captured fraction (listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}). siRNA knockdowns of RBM8A and EIF4A3 caused inviability of the cell line. We found that knocking-down MAGOH or the EJC-linked protein IGF2BP1 ([@bib46]) reduced retrotransposition by \~50%, consistent with a role in L1 proliferation; although these knockdowns also caused a reduction in viability of the cell line (see Discussion).

Split-tandem separation of compartment-specific L1 ORF-associated complexes {#s2-2}
---------------------------------------------------------------------------

To further test our hypothesis and better characterize the components of our L1 fraction, we conducted split-tandem affinity capture. [Figure 1](#fig1){ref-type="fig"} (panels D-F) illustrates the approach and displays the findings of the assay, which physically separated ORF1p/ORF2p-containing L1 RNPs from a presumptive \'only-ORF2p-associated\' population. Briefly, metabolically-labeled L1s were affinity captured by ORF2p-3xFLAG (first dimension) and the obtained composite was subsequently further fractionated by α-ORF1p affinity capture (second dimension, or split-tandem capture), resulting in α-ORF1p-bound and unbound (supernatant) fractions. The bound fraction was eluted from the affinity medium with LDS (elution). The supernatant and elution fractions were then mixed and analyzed by MS to ascertain proteomic differences between them. The α-ORF1p elution contained the population of proteins physically linked to *both* ORF2p and ORF1p, whereas the supernatant contained the proteins associated *only* with ORF2p (and, formally, those which have dissociated from the ORF1p/ORF2p RNP). The results corroborated our previous observations that: (i) almost all of the ORF1p partitioned into the elution fractions, (ii) a quarter of the ORF2p (\~26%) followed ORF1p during the α-ORF1p affinity capture, (iii) roughly half of the UPF1 (\~55%) followed ORF1p, and (iv) most of the PCNA (\~87%) remained in the ORF1p-depleted supernatant fraction ([Figure 1F](#fig1){ref-type="fig"}, and consistent with prior estimates based on protein staining and western blotting \[[@bib96]\]); thus (v) supporting the existence of at least two distinct populations of L1-ORF-protein-containing complexes in our affinity purifications.

The population eluted from the α-ORF1p affinity medium ([Figure 1D](#fig1){ref-type="fig"}, far right gel lane, and nodes located in the upper right of the graph, panel F) is consistent with the composition of the ORF1p/ORF2p-containing L1 RNP suggested above. Our split-tandem separation segregated the constituents of the L1 fraction comparably to the RNase-sensitivity assay, both in terms of which proteins co-segregated with ORF1p/ORF2p (compare [Figure 1C and F](#fig1){ref-type="fig"}, blue nodes, upper right of graphs) as well as those which appear to be linked only to ORF2p (compare [Figure 1C and F](#fig1){ref-type="fig"}, magenta nodes, lower left of the graphs). The ORF1p/ORF2p RNPs obtained by split-tandem capture included putative in vivo interactions associated with both α-ORF1p and α-ORF2p I-DIRT affinity capture experiments; whereas the unbound, ORF1p-independent fraction includes proteins previously observed as significant only in α-ORF2p I-DIRT experiments ([Table 1](#table1){ref-type="table"}). Analysis of the nodes whose degree of ORF1p association was similar to that of UPF1 (blue nodes exhibiting ≥55% ORF1p co-partitioning, [Figure 1F](#fig1){ref-type="fig"}) revealed that they map ontologically to a 'cytoplasmic ribonucleoprotein granule' classification (GO:0036464, p ≈ 6 × 10^−8^; see Discussion). In contrast, all sixteen proteins exhibiting ORF1p co-partitioning approximately equal to or less than that of ORF2p were predominantly found in the supernatant fraction and were enriched for cell-compartment-specific association with the nucleus (GO:0005634, p ≈ 4 × 10^−5^; [Figure 1F](#fig1){ref-type="fig"}: all magenta nodes ≤36%). These two fractions therefore appear to be associated with different cell compartments, reaffirming our postulate: the ORF1p/ORF2p-containing population is a cytoplasmic intermediate related to the canonical L1 RNP typically ascribed to L1 assembly in the literature, and the predominantly ORF2p-associated population comprises a putative nuclear interactome.

From the same analysis, we noted that PURA, PURB, PCNA, and TOP1 which all partition predominantly with nuclear L1, exhibited an ontological co-enrichment (termed \'nuclear replication fork,\' GO:0043596, p ≈ 3 × 10^−4^). The nodes representative of PURA, PURB, and PCNA appeared to exhibit a striking proximity to one another, suggesting highly similar co-fractionation behavior potentially indicative of direct physical interactions. In an effort to examine this possibility, we graphed the frequency distribution of the proximities of all three-node-clusters observed within [Figure 1F](#fig1){ref-type="fig"}, revealing the likelihood of the PURA/PURB/PCNA cluster to be p=3.2×10^−7^ (see Appendix 1). We therefore concluded that PURA, PURB, PCNA, and (perhaps at a lower affinity) TOP1, likely constitute a physically associated functional module interacting with L1. In further support of this assertion, we noted that known functionally linked protein pairs PABPC1/PABPC4 (cytoplasmic) ([@bib46]; [@bib49]) and HSPA8/HSPA1A (nuclear) ([@bib46]; [@bib74]) also exhibited comparable co-partitioning by visual inspection, and statistical testing of these clusters revealed the similarity of their co-partitioning to be significant at p ≈ 0.001 for the former, and p ≈ 0.0002 for the latter. The observed variation in co-partitioning behavior between the different proteins comprising the nuclear L1 fraction might reflect the presence of multiple distinctive (sub)complexes present within this population.

To validate our hypothesis that these proteins are associated with ORF2p in the nucleus, possibly engaged with host genomic DNA, we carried out ORF2p-3xFLAG affinity capture from chromatin-enriched sub-cellular fractions and found that the co-captured proteins we identified ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) overlapped with those described above as nuclear interactors, including: PARP1, PCNA, UPF1, PURA, and TOP1. We previously demonstrated that silencing PCNA expression adversely affects L1 retrotransposition ([@bib96]), in this study we found that knocking down TOP1 approximately doubled retrotransposition frequency, while a more modest 1.4x increase effect was observed for PURA, and no substantial effect was observed for PURB, compared to a scrambled siRNA control. In contrast, over-expression of PURA reduced retrotransposition to \~20% of the expected level ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). IPO7 was also observed among the putative ORF2p co-factors within the chromatin enriched fraction, congruent with its matching behavior in [Figure 1C and F](#fig1){ref-type="fig"}. Notably, IPO7 functions as a nuclear import adapter for HIV reverse transcription complexes ([@bib28]). Several other proteins that were observed did not previously exhibit I-DIRT specificity ([Supplementary file 3](#supp3){ref-type="supplementary-material"}).

L1 RNA and LEAP activity in affinity captured fractions {#s2-3}
-------------------------------------------------------

Because the L1 RNA is an integral component of proliferating L1s, and because we observed that interactions between ORF2p, ORF1p, and some host proteins were sensitive to treatment with RNases, we sought to characterize the RNAs present in our samples. We extracted RNAs from each of the three fractions produced by split-tandem affinity capture ([Figure 1D](#fig1){ref-type="fig"}) and carried out RNA sequencing; [Figure 2A](#fig2){ref-type="fig"} displays the sequence coverage observed across the entirety of our synthetic L1 construct in each fraction, revealing a normalized \~2 fold difference in abundance between the elution and supernatant fractions. Synthetic L1s constituted \~60% of the mapped, annotated sequence reads in the fractions eluted from the α-FLAG and α-ORF1p affinity media, and \~30% of the reads in the ORF1p-depleted supernatant fraction; sequencing reads mapping to protein coding genes made up the majority of the remaining annotated population in all fractions. We observed that a substantial number of reads mapped to unannotated regions of the human genome, in particular in the supernatant fraction, enriched for putative nuclear L1 complexes; the breakdown of mapped and annotated sequencing reads is summarized in [Figure 2B](#fig2){ref-type="fig"} and expanded in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

![Transcriptomic and enzymatic analysis of split-tandem RNP fractions.\
(**A**) *RNA sequencing affinity captured L1s*: L1 complexes were obtained by split-tandem affinity capture, as in [Figure 1D](#fig1){ref-type="fig"} (simplified schematic shown); RNA extracted from these three fractions was subjected to next-generation sequencing. The results are summarized with respect to coverage of the synthetic L1 sequence (see schematic with nucleotide coordinates) as well as the relative quantities of mapped, annotated reads (pie charts; the mean of duplicate experiments is displayed). (**B**) *Summary of sequencing reads*: displays the total number of sequencing reads that mapped to our reference library, the subset of mapped reads carrying a genome annotation, and the number of reads that corresponding to L1, both raw and normalized (see Materials and methods and [Supplementary file 4](#supp4){ref-type="supplementary-material"}). The mean of duplicate experiments is displayed; ±indicates the data range. (**C**) *LINE-1 element amplification protocol (LEAP) of affinity captured L1s*: L1 complexes were obtained from full length synthetic L1 (pLD401) and an otherwise identical *ΔORF1* construct (pLD561) following the same experimental design as in (**A**), except that elution from α-ORF1p affinity medium was done natively, by competitive elution. In this assay, L1 cDNAs are produced, in cis, by ORF2p catalyzed reverse transcription of L1 RNAs; the resulting cDNAs by were measured by quantitative PCR and presented as relative quantities normalized to pLD401 input ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). The mean of duplicate experiments is displayed; error bars indicate the data range.](elife-30094-fig2){#fig2}

Retrotransposition-competent L1 RNPs form in cis, with ORF proteins binding to the L1 RNA that encoded them ('*cis* preference'), presumably at the site of translation in the cytoplasm ([@bib57]; [@bib102]). Given that ORF1/2p partitioned to the split-tandem elution fraction (cytoplasmic) along with the greater fraction of L1 RNA, yet only ORF2p and a lesser portion of the L1 RNA were observed in the supernatant (nuclear), an important consideration regarding these fractions is: to what extent they contain L1 macromolecules capable of proliferation. To address this question, we performed the LINE-1 element amplification protocol (LEAP) on split-tandem affinity captured fractions ([Figure 2C](#fig2){ref-type="fig"}; [Supplementary file 4](#supp4){ref-type="supplementary-material"}), including a *ΔORF1* construct (pLD561) as a control ([@bib96]). LEAP is currently the best biochemical assay for functional co-assembly of L1 RNA and proteins ([@bib57]); it measures the ability of ORF2p to amplify its associated L1 RNA by reverse transcription. To execute LEAP on the α-ORF1p affinity captured fraction, we developed a competitive di-peptide elution reagent based on the linear peptide sequence used to generate the α-ORF1p 4H1 monoclonal antibody: residues 35--44 in ORF1p (\[[@bib52]; [@bib96]\]; see Materials and methods). We were thus able to assay the partitioning of enzymatic activity within the different populations of copurifying proteins in a split-tandem affinity capture experiment. Our data showed robust LEAP activity in both nuclear and cytoplasmic split-tandem supernatant and elution fractions. We note that our 3xFLAG eluted fractions have been shown to possess \~70 fold higher specific activity than L1 RNPs obtained by sucrose cushion velocity sedimentation ([@bib96]), hence the activity levels detected far exceed those obtained by sedimentation.

ORF1p/ORF2p immunofluorescence protein localization {#s2-4}
---------------------------------------------------

Although our proteomic and biochemical analyses supported the existence of distinctive nuclear and cytoplasmic L1 populations, our prior immunofluorescence (IF) analyses did not reveal an apparent nuclear population, leading us to revisit IF studies. Previously, IF of ORF1p and ORF2p in HeLa and HEK-293T cells yielded two striking observations: (i) ORF2 expression was seemingly stochastic, with ORF2p observed in \~30% of cells; and (ii) while ORF1p and ORF2p co-localized in cells that exhibited both, we did not observe an apparent nuclear population of either protein ([@bib96]). Subsequently, we noted an absence of mitotic cells from these preparations. Reasoning that these cells were lost due to selective adherence on glass slides, and noting that cell division has been reported to promote L1 transposition ([@bib106]; [@bib87]), we repeated the assays using puromycin-selected Tet-on HeLa cells grown on fibronectin coated coverslips. The results are shown in [Figure 3](#fig3){ref-type="fig"}.

![Immunofluorescent imaging reveals ORF1p expression is required for nuclear ORF2p staining.\
(**A**) Puromycin-selected HeLa-M2 cells containing pLD401 (Tet promoter, \[*ORFeus*-Hs\] full L1 coding sequence, ORF2p-3xFLAG, top two rows) or pLD561 (Tet promoter, *ΔORF1*, ORF2p-3xFLAG, bottom row) were plated on fibronectin-coated coverslips and induced for 24 hr with doxycycline prior to fixation and staining. With pLD401, the previously-observed pattern of cytoplasmic-only ORFs (top row) and a new pattern of pairs of cells displaying ORF2p in the nucleus (middle row) were apparent. When ORF1p was omitted from the construct (pLD561, bottom row), nuclear ORF2p was not apparent. Scale bars: 10 μm. (**B**) *Statistical analysis of the distances between pairs of ORF2p + nuclei as compared to random*: Violin plots of the distributions of shortest distances between 1000 pairs of randomly selected nuclei ('no') and the observed pairs of ORF2p + nuclei ('yes') in cells transfected with pLD401; n = 262 cells, 47 nuclear ORF2+. \*\*\*p=3.955 × 10^−11^ (Welch\'s t-test).\
10.7554/eLife.30094.007Figure 3---source data 1.Source data used in the analysis of ORF2p+ inter nuclear distance analysis: [Figure 3](#fig3){ref-type="fig"} and [Supplementary file 5](#supp5){ref-type="supplementary-material"}.](elife-30094-fig3){#fig3}

The modified IF assay corroborated our prior results in that nearly all the cells exhibited cytoplasmic ORF1p and a minority subset of \~1/3^rd^ also exhibited co-localized cytoplasmic ORF2p ([Figure 3A](#fig3){ref-type="fig"}, top row). We also observed an uncommon and previously unrecognized subpopulation of cells, consisting of pairs exhibiting nuclear localized ORF2p ([Figure 3A](#fig3){ref-type="fig"}, middle row); because these cells occurred in proximal pairs, we presumed them to have recently gone through mitosis. Statistical analysis of microscopy images displaying cells with nuclear localized ORF2p confirmed their proximities to be significantly closer than those of randomly selected cells ([Figure 3B](#fig3){ref-type="fig"}; [Supplementary file 5](#supp5){ref-type="supplementary-material"}). Expression of *ORF2* in the absence of *ORF1* (*ΔORF1*; pLD561) resulted in the majority of cells exhibiting cytoplasmic ORF2p, consistent with our previous work ([@bib96]). We did not observe instances of nuclear ORF2p using the *ΔORF1* construct ([Figure 3A](#fig3){ref-type="fig"}, bottom row), suggesting that ORF1p is required for ORF2p nuclear localization (see Discussion). In a separate study, including more detailed analyses of ORF protein localization, [@bib71] observed that both ORF proteins enter the nucleus of HeLa cells during mitosis, however, nuclear ORF1p does not seem to be physically associated with nuclear ORF2p (see Discussion). Taken together, the data obtained from the modified IF experiments aligned well with our proteomic and biochemical data; L1 expression resulted in *at least* two distinct populations: cytoplasmic complexes containing both ORF1p and ORF2p, and nuclear complexes containing ORF2p while potentially lacking ORF1p.

The effects of retrotransposition-blocking point mutations on the interactomes of affinity captured L1 RNPs {#s2-5}
-----------------------------------------------------------------------------------------------------------

Based on the hypothesis that our composite purifications contain bona fide nuclear intermediates, we decided to explore the effects of catalytic point mutations within the ORF2p endonuclease and reverse transcriptase domains, respectively. We reasoned that such mutants may bottleneck L1 intermediates at the catalytic steps associated with host gDNA cleavage and L1 cDNA synthesis, potentially revealing protein associations that are important for these discrete aspects of target-primed reverse transcription (TPRT), the presumed mechanism of L1 transposition ([@bib63]; [@bib29]; [@bib18]). For this we used an H230A mutation to inactivate the endonuclease activity (EN^-^/pLD567), and a D702Y mutation to inactivate the reverse transcriptase activity (RT^-^/pLD624) ([@bib96]). [Figure 4](#fig4){ref-type="fig"} illustrates the approach and displays the findings of our assay. Broadly, while we observed comparable RNA-level properties between samples ([Figure 4B](#fig4){ref-type="fig"}, [Supplementary file 4](#supp4){ref-type="supplementary-material"}), our findings revealed several classes of distinctive protein-level behaviors ([Figure 4C](#fig4){ref-type="fig"}). Two classes of behavior appeared to be particularly striking: (1) the yield of constituents of cytoplasmic L1s was reduced, relative to WT, by the EN^-^ mutation, yet elevated by the RT^-^ mutation ([Figure 4C](#fig4){ref-type="fig"}, left side); and (2) numerous constituents of nuclear L1s were elevated in yield by the EN^-^ mutation but reduced or nominally unchanged, relative to WT, by the RT^-^ mutation ([Figure 4C](#fig4){ref-type="fig"}, right side). With respect to the second group, IPO7, NAP1L4, NAP1L1, FKBP4, HSP90AA1, and HSP90AB1 were all elevated in the EN^-^ mutants, potentially implicating these proteins as part of an L1 complex (or complexes) immediately preceding DNA cleavage. Notably, there is a third class of proteins, including PURA/B, PCNA, TOP1, and PARP1, that all respond similarly to both EN^-^ and RT^-^ mutants compared to WT, exhibiting reduced associations with the mutant L1s; although, the RT^-^ mutant showed a larger effect size on the PURA/B proteins. These data suggest that cleavage of the host genomic DNA by ORF2p fosters associations between L1 and this third class of proteins, but that interactions with PURA/B may be further enhanced by L1 cDNA production. Other nuclear L1 proteins: HSPA8, HAX1, HSPA1A, TUBB, and TUBB4B were increased in both mutants. To better visualize the range of behaviors exhibited by our proteins of interest, and the population at large, we cross-referenced the relative enrichments of each protein detected in both experiments, shown in [Figure 4D](#fig4){ref-type="fig"}. We noted the same striking trend mentioned above, that two seemingly opposite behavioral classes of interactors could also be observed globally among all proteins associating with ORF2p catalytic mutants (see [Figure 4C](#fig4){ref-type="fig"}, left side and right side, and [Figure 4D](#fig4){ref-type="fig"}), creating the crisscross pattern displayed (see also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Notably, the pattern observed appears to track with the relative behavior of ORF1p, which, along with other cytoplasmic L1 factors is elevated in RT^-^ mutants and reduced in EN^-^ mutants. We therefore speculate that the sum of observed interactomic changes include effects attributable directly to the catalytic mutations as well as potential indirect effects resulting in increased cytoplasmic RNPs (including ORF1p)in the RT^-^ mutant.

![Catalytic inactivation of ORF2p alters the L1 interactome: L1s were affinity captured from cells expressing enzymatically active ORF2p-3xFLAG sequences (pLD401, WT), a catalytically inactivated endonuclease point mutant (pLD567; H230A, EN^-^), and a catalytically inactivated reverse transcriptase point mutant (pLD624; D702Y, RT^-^). These were analyzed by next-generation RNA sequencing and quantitative MS.\
(**A**) *Proteomic workflow*: WT L1s were captured from heavy-labeled cells, EN^-^ and RT^-^ L1s were captured from light-labeled cells. WT and either EN^-^ or RT^-^ fractions were mixed after affinity capture, in triplicate, and the relative abundance of each co-captured protein in the mixture was determined by quantitative MS. (**B**) *L1 RNA yield and coverage between different preparations*: As in [Figure 2A](#fig2){ref-type="fig"}, RNA extracted from 3xFLAG eluates originating from pLD401, pLD567, and pLD624 were subjected to next-generation sequencing. The results are summarized with respect to coverage of the synthetic L1 sequence (see schematic with nucleotide coordinates) as well as the relative quantities of mapped, annotated reads. The mean of duplicate experiments is displayed. (**C**) I-DIRT significant proteins displayed were detected in at least two replicates. All values were normalized to ORF2p. Data are represented as mean ±SD. Triangles (▵) mark proteins whose levels of co-capture did not exhibit statistically significant differences in the mutant compared to the WT. A single or double asterisk denotes a statistically significant difference between the relative abundances of the indicated protein in EN^-^ and RT^-^ mutants: p-values of between 0.05--0.01 (\*) and below 0.01 (\*\*), respectively. Gray horizontal bars on the plot mark the 2x (upper) and 0.5x (lower) effect levels. (**D**) The double histogram plot displays the distributions of all proteins identified in at least two replicates, in common between both EN/WT (TOP) and RT/WT (LOWER) affinity capture experiments. The x-axis indicates the relative recovery of each copurifying protein and the y-axis indicates the number of proteins at that value (binned in two unit increments). The data are normalized to ORF2p. The relative positions of ORF2p and ORF1p are marked by colored bars. Differently colored lines illustrate the relative change in positions of the proteins within the two distributions (as indicated). Colored lines denote I-DIRT significance, with magenta lines indicating a statistically significant shift in position (p≤0.05) within the two distributions and green lines indicating that statistical significance was not reached (entities labeled in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). A cluster of magenta lines can be seen to track with ORF1p (red line, upper and lower histogram), and another cluster can be seen to behave oppositely, creating a crisscross pattern in the center of the diagram. A similar crisscross pattern is exhibited by many gray lines.](elife-30094-fig4){#fig4}

Dynamics of L1 RNPs in vitro {#s2-6}
----------------------------

We next decided to measure the in vitro dynamics of proteins copurifying with affinity captured L1s, reasoning that proteins with comparable profiles are likely candidates to be physically linked to one another or otherwise co-dependent for maintaining stable interactions with L1s. To achieve this, we first affinity captured heavy-labeled, affinity-tagged L1s and subsequently incubated them, while immobilized on the medium, with light-labeled, otherwise identically prepared cell extracts from cells expressing untagged L1s ([@bib64]). In this scenario, heavy-labeled proteins present at the zero time point are effectively 'infinitely diluted' with light-labeled cell extract. The exchange of proteins, characterized by heavy-labeled proteins decaying from the immobilized L1s and being replaced by light-labeled proteins supplied by the cell extract, was monitored by quantitative MS. These experiments were conducted using constructs based on the naturally occurring L1RP sequence ([@bib20]; [@bib96]; [@bib53]). [Figure 5](#fig5){ref-type="fig"} illustrates the approach and displays the findings of our assay. We observed three distinctive clusters of behaviors ([Figure 5B,C](#fig5){ref-type="fig"}). Notably, ORF1p, ZCCHC3, and the cytoplasmic poly(A) binding proteins clustered together, forming a relatively stable core complex. Exhibiting an intermediate level of relative in vitro dynamics, UPF1 and MOV10 clustered with TUBB, TUBB4B, and HSP90AA1. A third, and least stable, cluster consisted of only nuclear L1 interactors.

![Monitoring coordinated dissociation and exchange exhibited by L1 interactors in vitro: L1s were affinity captured from heavy-labeled cells expressing ORF2p-3xFLAG in the context of the naturally occurring L1RP sequence (pMT302); the stabilities of the protein constituents of the captured heavy-labeled L1 population were monitored in vitro by competitive exchange with light-labeled cell extracts containing untagged L1s (pMT298) ([@bib96]).\
(**A**) 3xFLAG-tagged L1s were captured from heavy-labeled cells and then, while immobilized on the affinity medium, were treated with an otherwise identically prepared, light-labeled, untagged-L1-expressing cell extract. Untreated complexes were compared to independently prepared complexes incubated for 30 s, 5 min, and 30 min, (respectively) to determine the relative levels of in vivo assembled heavy-labeled interactors and in vitro exchanged light-labeled interactors, using quantitative MS. (**B**) The results were plotted to compare the percentage of heavy-labeled protein versus time. I-DIRT significant proteins from [Table 1](#table1){ref-type="table"} are highlighted if present. Three clusters were observed (as indicated). (**C**) The cosine distance between the observed I-DIRT significant proteins was plotted along with time.](elife-30094-fig5){#fig5}

Multidataset integration {#s2-7}
------------------------

Having observed coordinated and distinctive behaviors exhibited by groups of L1 interacting proteins across several distinctive biochemical assays, we then integrated the data and calculated the behavioral similarity of the I-DIRT-significant interactors, producing a dendrogram; [Figure 6](#fig6){ref-type="fig"} displays their relative similarities. A cluster containing the putative cytoplasmic L1 components (MOV10, UPF1, ZCCHC3, PABC1/4, ORF1p) was observed, as was a cluster containing PURA/B, PCNA, TOP1, PARP1, aligning with our assessments of the separated datasets ([Figures 1](#fig1){ref-type="fig"}, [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). In addition to these, we also observed three distinctive clusters derived from the nuclear L1 interactome. We believe that this is likely to reflect the presence of a collection of distinctive macromolecules.

![Interactomic data integration\
(**A**) All MS-based affinity proteomic experiments presented were combined and analyzed for similarities across all I-DIRT significant proteins, producing five groupings. Distance are presented on a one-unit arbitrary scale (see Materials and methods: Mass Spectrometry Data Analysis). (**B**) The traces of each protein in each cluster, across all experiments, are displayed. The y-axis indicates the raw relative-enrichment value and the x-axis indicates the categories of each experiment-type. Each category is as wide as the number of replicates or time-point samples collected.](elife-30094-fig6){#fig6}

Discussion {#s3}
==========

In this study we have characterized biochemical, interatomic, enzymatic, and cellular localization properties of ectopically expressed L1s. Through the assays explored, we observed discrete and coordinated behaviors, permitting us to refine our model of L1 intermediates, diagrammed in [Figure 7](#fig7){ref-type="fig"}. We propose a cytoplasmic L1, composed of ORF1/2 p, L1 RNA, PABPC1/4, MOV10, UPF1, and ZCCHC3, that constitutes an abundant, canonical RNP intermediate often referred to in the literature. MOV10, UPF1, and ZCCHC3 are apparently substoichiometric to ORF2p in our preparations, therefore it may be that only a subset of cytoplasmic intermediates engages these host restriction factors. On the other hand, this apparent relative abundance may simply reflect a lower in vitro stability of UPF1 and MOV10 within this complex ([Figure 5](#fig5){ref-type="fig"}). Although ORF1p is apparently required for efficient ORF2p nuclear entry, we also propose a second more complicated population, lacking (or with significantly less) ORF1p, that constitutes nuclear or pre- dominantly nuclear L1 macromolecules. We note that *Alu* elements exhibit ORF2p-dependent mobilization that does not require ORF1p, but appears to be enhanced by ORF1p in some contexts ([@bib23]; [@bib100]); this is not true for L1 or processed pseudogenes, and we conclude *Alu* RNPs likely exploit an alternate mechanism of nuclear entry. The nuclear L1 population is enriched for factors linked to DNA replication and repair, including PURA, PURB, PCNA, TOP1, and PARP1; we propose that these proteins, along with ORF2p, form part of a direct intermediate of TPRT, although these components may not all act in synergy. Our proposals are broadly supported by the findings of [@bib71], who present data to support the hypothesis that PCNA-associated ORF2p is not appreciably associated with ORF1p, and also identified TOP1 and PARP1 in complex with ORF2p/PCNA.

![Refined interatomic model: Our results support the existence of distinct cytoplasmic and nuclear L1 interactomes.\
Affinity capture of L1 via 3xFLAG-tagged ORF2p from cell extracts results in a composite purification consisting of several macromolecular (sub)complexes. Among these, we propose a canonical cytoplasmic L1 RNP (**depicted**) and one or more nuclear macromolecules. UPF1 exhibited equivocal behavior within our fractionations and was also co-captured with chromatin associated ORF2p, suggesting it participates in both cytoplasmic and nuclear L1 interactomes. Within the nuclear L1 interactome, our data support the existence of a physically linked entity consisting of (at least) PCNA, PURA/B, TOP1, and PARP1 (**depicted**).](elife-30094-fig7){#fig7}

Although the protein purification approach was the similar, we observed an apparently larger proportion of L1 RNA in our recent preparations than in our previous study. We reported that L1 constituted \~25% of mapped reads previously ([@bib96]); a comparable result was obtained when we reanalyzed that data using the pipeline described here (see Materials and methods): \~93% of reads in our reanalyzed 2013 dataset mapped to the human genome, and L1 constituted \~20% of reads mapped to annotated features ('annotated reads') in 3xFLAG eluates. In this study we report that \~60% of annotated reads mapped to synthetic L1 in 3xFLAG eluates ([Figure 2A](#fig2){ref-type="fig"}). The higher proportion of L1 recovered may be due to the combination of higher fidelity RNA preparative methods and advanced sequencing technology used here; we observed \~10x more total reads mapping to L1 and comparatively improved, more uniform coverage across the entire L1 sequence, likely explaining the discrepancy. We also noted that the number of normalized reads mapped to L1 in our initial 3xFLAG elutions ('input') and subsequent tandem-purified α-ORF1p elutions were comparable, and yet \~1/2 as many were seen in the α-ORF1p supernatant fraction ([Figure 2A,B](#fig2){ref-type="fig"}). We suspect that this is due to saturation in library preparations or sequencing steps for the 'input' and 'elution' fractions, but conclude that more L1 RNA is in the 'cytoplasmic' elution fraction than the 'nuclear' supernatant.

We observed substantial and comparable LEAP activity in both our tandem-purified ORF1p+ ('elution') and ORF1p-- (immuno-depleted 'supernatant') populations ([Figure 2C](#fig2){ref-type="fig"}, [Supplementary file 4](#supp4){ref-type="supplementary-material"}). To our knowledge, these represent the simplest and purest endogenously assembled L1 RNPs yet reported that exhibit robust signal in the LEAP assay. We note that, our results demonstrating robust activity in the nuclear-enriched supernatant fraction (depleted of ORF1p) may contrast with previous reports of reduced LEAP activity in constructs where ORF1p RNA binding was compromised ([@bib57]), but our fractions merit further study and comparisons on the basis of ORF2p and RNA levels to determine specific activity.

Cytoplasmic L1 macromolecules {#s3-1}
-----------------------------

ORF1p, MOV10, UPF1, and ZCCHC3 are released from L1 RNPs by treatment with RNases ([Figure 1](#fig1){ref-type="fig"}), indicating the importance of the L1 RNA in the maintenance of these interactions. In this context, the L1 ORF and poly(A) binding proteins support L1 proliferation ([@bib57]; [@bib21]; [@bib102]), whereas ZCCHC3 ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) and MOV10 ([@bib33]; [@bib4]) function in repressive capacities. Although UPF1 might also be expected to operate in a repressive capacity through its role in nonsense mediated decay (NMD), we previously demonstrated that UPF1\'s role does not apparently resemble that of canonical NMD and it acts as an enhancer of retrotransposition despite negatively affecting L1 RNA and protein levels, supporting the possibility of repressive activity in the cytoplasm and proliferative activity in the nucleus ([@bib96]). Notably, MOV10 has been implicated in the recruitment of UPF1 to mRNA targets through protein-protein interactions ([@bib37]). However, we observed that MOV10 exhibited a greater degree of RNase-sensitivity than UPF1, indicating that, if MOV10 directly modulates the UPF1 interactions with L1, a sub-fraction of UPF1 exhibits a distinct behavior (UPF1 is \~62% as sensitive to RNase treatment as MOV10, [Figure 1C](#fig1){ref-type="fig"}). Bimodal UPF1 behavior can also be seen in split-tandem capture experiments, only about half of the UPF1 exhibited ORF1p-like partitioning with the canonical L1 RNP (Figure 1F). Moreover, UPF1 was recovered with L1s affinity captured from fractionated chromatin (further discussed below), and only about half of the UPF1 exhibits ORF1p-like partitioning with the canonical L1 RNP ([Figure 1F](#fig1){ref-type="fig"}). Presumably, the RNase-sensitive fraction, released in concert with MOV10, is the same fraction observed in cytoplasmic L1s obtained by split-tandem capture. In contrast, PABPC1 and C4 exhibit strong ORF1p-like partitioning (comparable to MOV10), but appear wholly insensitive to RNase treatment. This is most likely due to the fact that neither RNase A nor T1 cleave RNA at adenosine residues ([@bib99]; [@bib108]); hence poly(A) binding proteins may not be ready targets for release from direct RNA binding by the assay implemented here (or generally, using these ribonucleases). Failure to release ORF2p into the supernatant upon RNase treatment is expected due to its immobilization upon the affinity medium ([@bib20]). However, we note that ORF2p binding to the L1 RNA has also been proposed to occur at the poly(A) tail ([@bib26]), raising the related possibility of close physical association on the L1 RNA between ORF2p and PABPC1/4 in cytoplasmic L1 RNPs. ORF1p, PABPC1/4, MOV10, ZCCHC3, and UPF1, all behaved comparably in response to EN^-^ and RT^-^ catalytic mutations, decreasing together in EN^-^ mutants, and increasing together in RT^-^ mutants ([Figure 4C](#fig4){ref-type="fig"}). Moreover, when the exchange of proteins within L1 RNPs was monitored directly, PABPC1/4 and ZCCHC3 exhibited nearly identical stability, well above the background distribution; UPF1 and MOV10 also exhibited comparable kinetics to one another, falling into an intermediary stability cluster ([Figure 5B,C](#fig5){ref-type="fig"}).

RNase-sensitivity was displayed by numerous proteins not previously identified as putative L1 interactors ([Table 1](#table1){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}; \[[@bib96]\]). A known limitation of I-DIRT (and many SILAC-based analyses) is that it cannot discriminate non-specific interactors from specific but rapidly exchanging interactors ([@bib101]; [@bib64]; [@bib89]). Our samples likely contain rapidly exchanging, physiologically relevant factors that were not revealed by I-DIRT under the experimental conditions used. With this in mind, we note members of the exon junction complex (EJC), RBM8A (Y14), EIF4A3 (DDX48), and MAGOH, are among our RNase-sensitive constituents, all exhibiting a similar degree of RNase-sensitivity ([Figure 1C](#fig1){ref-type="fig"}, labeled black dots). Crucially, these proteins are physically and functionally connected to UPF1 (reviewed in \[[@bib86]\]), and physically to MOV10 ([@bib37]), both validated L1 interactors. We therefore hypothesize that EJCs may constitute bona fide L1 interactors missed in our original screen. This may seem unexpected because canonical L1 RNAs are thought not to be spliced, but this assumption has been challenged by one group ([@bib9]), and splicing-independent recruitment of EJCs has also been demonstrated ([@bib13]). Perhaps more compelling, EJC proteins exhibited a striking similarity in RNase-sensitivity to MOV10 ([Figure 1C](#fig1){ref-type="fig"}). EIF4A3 has been suggested to form an RNA-independent interaction with MOV10 ([@bib37]), and MOV10 is a known negative regulator of L1, making it attractive to speculate that these proteins were recruited and released in concert with MOV10 and/or UPF1.

Ectopically expressed canonical L1 RNPs have been shown to accumulate in cytoplasmic stress granules ([@bib25]; [@bib35]), and our observation of UPF1, MOV10, and MAGOH in the RNase-sensitive fraction is consistent with this characterization ([@bib44]). However, the additional presence of EIF4A3 and RBM8A suggested that our RNPs may instead overlap with IGF2BP1 (IMP1) granules, reported to be distinct from stress granules ([@bib46]; [@bib103]). Consistent with this possibility, we observed IGF2BP1, YBX1, DHX9, and HNRNPU within the mixture of co-captured proteins ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). We did not, however, observe canonical stress granule markers G3BP1 or TIA1 ([@bib36]; [@bib44]; [@bib25]). Surprisingly, siRNA knockdown of IGF2BP1 substantially reduced L1 retrotransposition; however, we note that the cytotoxicity associated with knocking-down EJC components may confound interpretation ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Given the result obtained, IGF2BP1 appears to support L1 proliferation. Consistent with an established function ([@bib10]; [@bib103]), IGF2BP1 granules may sequester and stabilize L1 RNPs in the cytoplasm, creating a balance of L1 supply and demand that favors proliferation over degradation. Although human L1 does not contain a known IRES, it is known that *ORF2* is translated by a non-canonical mechanism ([@bib1]), and IGF2BP1 may promote this ([@bib104]).

Nuclear L1 macromolecules {#s3-2}
-------------------------

The fraction eluted from the α-ORF1p medium contained the population of proteins physically linked to both ORF2p and ORF1p and greatly resembled the components released upon RNase treatment, hence these linkages primarily occur through the L1 RNA (or are greatly influenced by it). In contrast, the supernatant from the α-ORF1p affinity capture contained the proteins we speculate to be associated with ORF2p, but not ORF1p; moreover, fully intact RNA does not appear to be essential to the maintenance of these interactions. An exciting alternate interpretation to direct protein-protein linkage is that some of the L1 RNAs in this population may be at least partially hybridized to L1 cDNAs, which would render them RNase resistant: at the salt concentration used in our RNase assay (0.5 M; [Figure 1C](#fig1){ref-type="fig"}), RNase A is unlikely to cleave the RNA component of DNA/RNA hybrids ([@bib40]; [@bib105]), and such activity is not expected of RNase T1. This interpretation is supported by several pieces of indirect evidence: (1) the presence of well-known DNA binding factors ([Figure 1](#fig1){ref-type="fig"}); (2) the presence of several of these same factors (PARP1, PCNA, PURA, and TOP1) in ORF2p-3xFLAG affinity captured from enriched chromatin ([Supplementary file 3](#supp3){ref-type="supplementary-material"}); (3) The pronounced decrease in stable in vivo co-assembly of TOP1, PCNA, PARP1, PURA, and PURB in affinity captured L1 fractions harboring ORF2p EN^-^ and RT^-^ mutations ([Figure 4](#fig4){ref-type="fig"}), with a greater effect in RT^-^ mutations; and (4) our L1 preparations exhibit RT activity ([Figure 2C](#fig2){ref-type="fig"}, in vitro; as well as in vivo \[[@bib96]\]). If true, linkage of subcomplexes via DNA/RNA hybrids would further support the nuclear origin of much of this fraction; further study is needed. Notable within this group of putative nuclear interactors was the PURA/PURB/PCNA cluster ([Figure 1F](#fig1){ref-type="fig"}), with TOP1 also in close proximity, ontologically grouping to the nuclear replication fork (GO:0043596). Separately, a few physical and functional connections have been shown for PURA/PURB ([@bib54]; [@bib51]; [@bib72]), PCNA/TOP1 ([@bib93]), and PURA/PCNA ([@bib83]). Notably, PURA, PURB, and PCNA have been independently linked to replication-factor-C/replication factor-C-like clamp loaders ([@bib55]; [@bib42]). Given that we also observe tight clustering of protein pairs known to be physically and functionally linked, e.g. PABPC1/4 ([@bib46]; [@bib49]) and HSPA8/1A ([@bib46]; [@bib74]), and because we have established PCNA as a positive regulator of L1 retrotransposition ([@bib96]), we propose that the \[PURA/B/PCNA/TOP1\] group is a functional sub-complex of nuclear L1. In addition, although it does not cluster as closely to the \[PURA/B/PCNA/TOP1\] group, PARP1 is found within the putative nuclear L1 population and is functionally linked with PCNA, specifically stalled replication forks ([@bib12]; [@bib70]; [@bib107]). Further tying them together, these proteins all also exhibited substantial affinity capture yield decreases in response to mutations that abrogated ORF2p EN or RT activity ([Figure 4](#fig4){ref-type="fig"}). This is compelling because these ORF2p enzymatic activities are required in order for it to manipulate DNA and traverse the steps of the L1 lifecycle that benefit from physical association with replication forks. One caveat to this interpretation is that, while knocking down PCNA reduced L1 retrotransposition ([@bib96]), no such effect was observed for TOP1 or PURA/B, which led instead to mild increases in L1 activity ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). These proteins may be physically assembled within a common intermediate, but functionally antagonistic. HSP90 proteins were also observed in this fraction, and are also linked with stalled replication forks ([@bib5]; [@bib38]), but exhibited a distinctive response to catalytic mutants, accumulating in EN^-^ mutants while exhibiting a modest decrease in RT^-^ mutants. The recruitment of the ORF2p/PCNA complex to stalled replication forks has been also proposed by [@bib71].

As mentioned above, we previously speculated that an RNase-insensitive fraction of L1-associated UPF1 may support retrotransposition in conjunction with PCNA in the nucleus ([@bib6]; [@bib96] and [@bib71]). In contrast to other PCNA-linked proteins, catalytic inactivation of ORF2p did not robustly affect the relative levels of co-captured UPF1, and UPF1 behaved in a distinct manner during tandem capture. The equivocal behavior of UPF1 in several assays ([Figures 1](#fig1){ref-type="fig"}, [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) supports UPF1's association with both the putative cytoplasmic and nuclear L1 populations, the latter being additionally supported by the association of UPF1 with ORF2p-3xFLAG captured from chromatin ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). NAP1L4, NAP1L1, FKBP4, HSP90AA1, and HSP90AB1 ([@bib7]; [@bib17]; [@bib88]; [@bib85]; [@bib81]) are associated with RNA binding, involved in protein folding and unfolding, and function as nucleosome chaperones. An interesting possibility is that they have a nucleosome remodeling activity that may be required to allow reverse transcription to begin elongating efficiently, or for assembly of nucleosomes on newly synthesized DNA.

Future studies {#s3-3}
--------------

An obvious need is the continued validation of putative interactors by in vivo assays. Genetic knockdowns coupled with L1 insertion measurements by GFP fluorescence ([@bib80]) provide a powerful method to detect effects on L1 exerted by host factors. However, this approach can sometimes be limited by cell viability problems associated with important genes; it is therefore critical to control for this ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). IF and high-resolution microscopy may be useful to demonstrate co-localization of putative L1-associated proteins and may also be informative, warranting effort to identify appropriate antibodies and assay conditions. Bolstered by our analytical successes, RNA-sequencing, LEAP, and RNase-based affinity proteomics appear as notably high-value assays for further application-specific expansion and refinement.

Throughout this and our prior study ([@bib96]) we have used comparable in vitro conditions for the capture and analysis of L1 interactomes. However, we are aware that this practice has enforced a single biochemical 'keyhole' through which we have viewed L1-host protein associations. It is important to expand the condition space in which we practice L1 interactome capture and analysis in order to expand our vantage point on the breadth of L1-related macromolecules ([@bib39]). In concert with this, we must develop sophisticated, automated, reliable, low-noise methods to integrate biochemical, proteomic, genomic, and ontological data; the first stages of which we have attempted in the present study. Although we have used I-DIRT to increase our chances of identifying bona fide interactors ([@bib92]; [@bib96]), it is clear, and generally understood, that some proteins not making the significance cut-off will nevertheless prove to be critical to L1 activity ([@bib14]; [@bib64]; [@bib45]), such as demonstrated by our unexpected findings with IGF2BP1 ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Through further development, including reliable integration with diverse, publicly available interactome studies, we hope to enable the detection of extremely subtle physical and functional distinctions between (sub)complexes and their components, considerably enhancing reliable exploration and hypothesis formation. Furthermore, it is striking that no structures of assembled L1s yet exist; these are missing data that are likely to provide a profound advance for the mechanistic understanding of L1 molecular physiology. However, we believe that with the methods presented here, endogenously assembled ORF1p/ORF2p/L1*-*RNA-containing cytoplasmic L1 RNPs can be prepared at sufficiently high purity and yield ([Figure 1F](#fig1){ref-type="fig"}) to enable electron microscopy studies. Importantly, we have shown that our affinity captured fractions are enzymatically active for reverse transcription of the L1 RNA ([Figure 2C](#fig2){ref-type="fig"}; ([@bib96])), providing some hope that cryo-electron microscopy could be used to survey the dynamic structural conformations of L1s formed during its various lifecycle stages ([@bib94]).

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation                                            Source or reference            Identifiers                                                    Additional information
  or resource                                                                                                                                                                    
  ------------------------- ------------------------------------------------------ ------------------------------ -------------------------------------------------------------- ------------------------------------------------------------------------------------
  gene (human) LINE-1       *ORFeus*-Hs; L1RP                                      10.1016/j.cell.2013.10.021;\                                                                  
                                                                                   10.1186/1759-8753-2-2                                                                         

  cell line (human)         HEK-293T_LD                                            10.1016/j.cell.2013.10.021;\                                                                  Mycoplasma testing was done\
                                                                                   10.1128/MCB.06785--11                                                                         regularly and was negative. We received\
                                                                                                                                                                                 an authenticated cell line from the ATCC\
                                                                                                                                                                                 and subsequently made them blastomycin\
                                                                                                                                                                                 resistant so we validated cells by\
                                                                                                                                                                                 blastomycin resistance.

  transfected construct\    pLD401; pLD561; pLD567;\                               10.1016/j.cell.2013.10.021                                                                    
  (human)                   pLD624; pMT302; pMT289                                                                                                                               

  antibody                  anti-FLAG; anti-ORF1p                                  10.1016/j.cell.2013.10.021     Sigma-Aldrich\                                                 
                                                                                                                  Cat\# F1804,\                                                  
                                                                                                                  RRID:[AB_262044](https://scicrunch.org/resolver/AB_262044);\   
                                                                                                                  custom made,\                                                  
                                                                                                                  Abmart: 4H1                                                    

  peptide, recombinant\     ORF1p N-terminal\                                      this paper                                                                                    
  protein                   di-peptide                                                                                                                                           

  software, algorithm       Scripts for IF ([Figure 3](#fig3){ref-type="fig"});\   this paper                                                                                    Scripts are in [Supplementary file 5](#supp5){ref-type="supplementary-material"};\
                            formal analysis used custom\                                                                                                                         R code in -- <https://bitbucket.org/altukhov/line-1/>
                            R code throughout                                                                                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The preparation of L1 RNPs was carried out essentially as previously described ([@bib96], [@bib95]), with modifications described here. Briefly, HEK-293T~LD~ cells ([@bib21]) transfected with L1 expression vectors were cultured as previously described or using a modified suspension-growth SILAC strategy described below. L1 expression was induced with with 1 μg/ml doxycycline for 24 hr, and the cells were harvested and extruded into liquid nitrogen. In all cases the cells were then cryogenically milled ([@bib58]) and used in affinity capture experiments and downstream assays. Custom computer code written in the R programming language was used in the analysis of mass spectrometry and RNA sequencing data; it has been published on <https://bitbucket.org> ([@bib2]); a copy is archived at <https://github.com/elifesciences-publications/altukhov-line-1>.

Modified SILAC strategy {#s4-1}
-----------------------

Freestyle-293 medium lacking Arginine and Lysine was custom-ordered from Life Technologies, and heavy or light amino acids plus proline were added at the same concentrations previously described ([@bib96]), without antibiotics. Suspension-adapted HEK-293T~LD~ were spun down, transferred to SILAC medium and grown for \>7 cell divisions in heavy or light medium. On day 0, four (4) 1L square glass bottles each containing 200 ml of SILAC suspension culture at \~2.5 × 10^6^ cells/ml were transfected using 1 μg/ml DNA and 3 μg/ml polyethyleneimine 'Max' 40 kDa (Polysciences, Warrington, PA, \#24765). A common transfection mixture was made by pre-mixing 800 μg DNA and 2.4 mL of 1 mg/ml PEI-Max in 40 ml Hybridoma SFM medium (Life Technologies, Grand Island, NY, \#12045--076) and incubating for 20 min at room temperature (RT); 10 ml of the mixture was added to each bottle. On day 1, cells (200 ml) were split 1:2.5 (final two bottles each containing 250 mL) without changing the medium. On day 3, the cells were induced with 1 µg/ml doxycycline, and on day four the cells were harvested and extruded into liquid nitrogen. Aliquots were tested by western blot and the per-cell expression of both ORFs was indistinguishable from puromycin-selected material described previously (Appendix 1); transfection efficiency was assessed at \>95% by indirect immunofluorescence of expressed ORF proteins. The median lysine and arginine heavy isotope incorporation levels for cell lines presented in this study were \>90%, determined as previously described ([@bib96]).

RNase-sensitivity affinity capture {#s4-2}
----------------------------------

Four sets of 200 mg of light (L) and heavy (H) pLD401 transfected cell powders, respectively, were extracted 1:4 (w:v) with 20 mM HEPES-Na pH 7.4, 500 mM NaCl, 1% (v/v) Triton X-100 (extraction solution), supplemented with 1x protease inhibitors (Roche, Indianapolis, IN, \#11836170001). After centrifugal clarification, all of the L and H supernatants were pooled, respectively, and then split, resulting in two sets of cleared L and H extracts equivalent to duplicate 400 mg samples from each SILAC cell powder. These four samples were each subjected to affinity capture upon 20 μl α-FLAG magnetic medium. After binding and washing, one set of L and H samples were treated with a control solution consisting of 2 μl of 2 mg/ml BSA (Thermo Fisher Scientific, Waltham, MA, \#23209) and 50 μl extraction solution, v:v (Ctrl); the other set of L and H samples was treated with a solution of 2 μl 2 mg/ml RNase A/5000 u/ml RNase T1 (Thermo Fisher Scientific \#EN0551) and 50 μl extraction solution, v:v (RNase). Samples were then incubated 30 min at RT with agitation, the supernatant was removed, and the medium was washed three times with 1 ml of extraction solution. The retained captured material was eluted from the medium by incubation with 40 μl 1.1x LDS sample loading buffer (Life Technologies \#NP0007). To enable quantitative comparisons of fractions, the samples were combined, respectively, as follows: 30 ul each of the ^L^RNase with ^H^Ctrl, and 30 ul each of the ^L^Ctrl with ^H^RNase. These samples were reduced, alkylated and run until the dye front progressed \~6 mm on a 4--12% Bis-Tris NuPAGE gel (Life Technologies, as per manufacturer's instructions). The gels were subsequently subjected to colloidal Coomassie blue staining ([@bib15]) and the sample regions ('gel-plugs') excised and processed for MS analyses, as described below.

Split-tandem affinity capture {#s4-3}
-----------------------------

400 mg of light (L) and heavy (H) pLD401 transfected cell powders, respectively, were extracted and clarified as above. These extracts were subjected to affinity capture on 20 μl α-FLAG magnetic medium, 30 min at 4°C, followed by native elution with 50 μl 1 mg/ml 3xFLAG peptide (15 min, RT). 45 μl of the elution were subjected to subsequent affinity capture upon 20 μl α-ORF1 magnetic medium, resulting in a 45 μl supernatant (Sup) fraction depleted of ORF1p. Finally, the material was eluted (Elu) from the α-ORF1p medium in 45 μl 2.2x LDS sample loading buffer by heating at 70°C for 5 min with agitation. To enable quantitative comparisons of fractions the samples were combined, respectively, as follows: 28 μl each of the ^L^Sup with ^H^Elu, and 28 μl each of the ^L^Elu with ^H^Sup. These samples were then prepared as gel-plugs (as above) and processed for MS analyses, as described below.

Mass spectrometry sample preparation and data acquisition {#s4-4}
---------------------------------------------------------

Gel plugs were excised, cut into 1 mm cubes, de-stained, and digested overnight with enough 3.1 ng/μl trypsin (Promega, Madison, WI, \#V5280) in 25 mM ammonium bicarbonate to cover the pieces. In RNase-sensitivity and split-tandem SILAC analyses based on pLD401, as well as in vitro protein exchange experiments based on pMT302 and pMT289, an equal volume of 2.5 mg/ml POROS R2 20 µm beads (Life Technologies \#1112906) in 5% v/v formic acid, 0.2% v/v TFA was added, and the mixture incubated on a shaker at 4°C for 24 hr. Digests were desalted on Stage Tips ([@bib84]), eluted, and concentrated by vacuum centrifuge to \~10 μl. \~3 μl were injected per LC-MS/MS analysis. RNase-sensitivity and split-tandem samples were loaded onto a PicoFrit column (New Objective, Woburn, MA) packed in-house with 6 cm of reverse-phase C18 material (YMC^∗^Gel ODS-A, YMC, Allentown, PA). Peptides were gradient-eluted (Solvent A = 0.1 M acetic acid, Solvent B = 0.1 M acetic acid in 70% v/v acetonitrile, flow rate 200 nl/min) into an LTQ-Orbitrap-Velos or an LTQ-Orbitrap-XL mass spectrometer (Thermo Fisher Scientific) acquiring data-dependent CID fragmentation spectra. In vitro exchange samples were loaded onto an Easy-Spray column (ES800, Thermo Fisher Scientific) and gradient-eluted (Solvent A = 0.1% v/v formic acid in water, Solvent B = 0.1% v/v formic acid in acetonitrile, flow rate 300 nl/min) into an Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) acquiring data-dependent HCD fragmentation spectra. In SILAC experiments comparing inactivated ORF2p catalytic mutants to WT (based on pLD401 \[WT\], pLD567 \[EN^-^\], and pLD624 \[RT^-^\]) peptides were extracted from the gel in two 1 hr incubations with 1.7% v/v formic acid, 67% v/v acetonitrile at room temperature with agitation. Digests were partially evaporated by vacuum centrifugation to remove acetonitrile, and the aqueous component was desalted on Stage Tips. Peptides were loaded onto an Easy-Spray column (ES800, Thermo Fisher Scientific) and gradient-eluted (Solvent A = 0.1% v/v formic acid in water, Solvent B = 0.1% v/v formic acid in acetonitrile, flow rate 300 nl/min) into an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific) acquiring data-dependent fragmentation spectra (either CID spectra alone, or CID and HCD spectra).

Mass spectrometry data analysis {#s4-5}
-------------------------------

Raw files were submitted to MaxQuant ([@bib19]) version 1.5.2.8 for protein identification and isotopic ratio calculation. Searches were performed against human protein sequences (UP000005640, April 2016), custom L1 ORF1p and ORF2p protein sequences, common exogenous contaminants, and a decoy database of reversed protein sequences. Search parameters included fixed modification: carbamidomethyl (C); variable modification: Arg10, Lys8, methionine oxidation; razor and unique peptides used for protein quantitation; requantify: enabled. Contaminants, low-scoring proteins and proteins with one razor+unique peptides were filtered out from the MaxQuant output file 'proteingroups.txt'. The list of contaminants was uploaded from the MaxQuant web-site (<http://www.coxdocs.org/>; 'contaminants'). Additionally, proteins with the 'POTENTIAL CONTAMINANT' column value '+\' were filtered out. Proteins with at least two razor+unique peptides were retained for the analysis. H/(H + L) and L/(H + L) values were derived from unnormalized 'ratio H/L' values and were used for plotting label-swapped RNase-sensitivity and split-tandem data. Unnormalized 'ratio H/L' values were used to calculate H/(H + L) in ORF2p catalytic mutant comparisons and in vitro exchange experiments. These values have been referred to as 'affinities' within the Supplementary Materials. Normalization and clustering procedures applied to data presented in the figures ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) are detailed below and also in Appendix 1. Raw and processed data are available via ProteomeXchange with identifier PXD008542.

To plot RNase-sensitivity affinity capture results ([Figure 1C](#fig1){ref-type="fig"}), these data were normalized such that proteins that did not change upon treatment with RNases are centered at the origin. The mean value and standard deviation were calculated using the distribution of distances from the origin. The distance threshold for p-value=0.001 was calculated using the R programming language. A circle with radius equal to the threshold was plotted. Points with distances higher than the threshold were marked as black. To plot split-tandem affinity capture results ([Figure 1F](#fig1){ref-type="fig"}), these data were normalized such that the ORF1p affinity was set to one and the distribution median was maintained. Probabilities associated with selected clusters were calculated based on the frequency distributions of 2- and 3-node clusters present in the data. To plot EN^-^ and RT^-^ mutant affinity capture results ([Figure 4C](#fig4){ref-type="fig"}), the matrix of detected proteins for each experiment (EN^-^ and RT^-^) was filtered to retain only proteins detected in at least two replicate experiments. The difference between the affinity value of ORF2p and 0.5 value was calculated for each experiment. The affinities of each protein were shifted by the calculated difference. To determine the statistical significance of differentially co-captured proteins between EN^-^ or RT^-^ and WT, respectively, we used a 1-sample t-test and applied Benjamini-Hochberg p-value correction. To determine the statistical significance of differentially co-captured proteins between EN^-^ and RT^-^ we used an unpaired t-test and applied Benjamini-Hochberg p-value correction. To plot in vitro dynamics ([Figure 5B,C](#fig5){ref-type="fig"}), only proteins which were identified at all time points were used. The cosine similarity method was used to calculate distances between proteins, and hierarchical clustering was used to visualize these distances. To integrate and plot the combined data ([Figure 6](#fig6){ref-type="fig"}), we calculated Euclidean and cosine distances for each I-DIRT-significant protein pair present in each experiment. Euclidean distances were rescaled to the range (0, 0.9). Proteins not detected in any common experiments were assigned a Euclidian distance of 1 after rescaling. The total distance between protein pairs was calculated as d = log((rescaled Euclidean distance) \* (cosine distance)). This distance was rescaled to the range (0, 1). Hierarchical clustering was used to visualize the calculated distances.

Gene ontology (GO) analysis {#s4-6}
---------------------------

Genes corresponding to the proteins previously reported as significant by I-DIRT ([@bib96]) were tested for statistical overrepresentation using the default settings provided by <http://www.panthnerdb.org> ([@bib68], [@bib69]), searches were conducted using GO complete molecular function, biological process, and cellular compartment: all results are compiled in [Supplementary file 6](#supp6){ref-type="supplementary-material"}.

RNA sequencing sample preparation and data acquisition {#s4-7}
------------------------------------------------------

RNA fractions were obtained from fractions of L1 macromolecules isolated from pLD401 expressing cells by split-tandem affinity capture ([Figure 1D](#fig1){ref-type="fig"}) and from pLD567 and pLD624 expressing cells by affinity capture ([Figure 4](#fig4){ref-type="fig"}). The fractions were produced as described above, except few adjustments to favor RNA extraction. Identical stock solutions were used for making buffers but were diluted to working concentration with nuclease-free water (Thermo Fisher Scientific \#4387936) and supplemented with RNasin (Promega, Cat.\# N2511) -- 1:250 during sample extraction and 3xFLAG peptide elution, and 1:1000 during affinity media washing. 600 mg of cell powder was used per preparation, extracted as 3 × 200 mg and pooled after centrifugal clarification, producing \~3 ml of extract. The pooled extracts were combined with magnetic affinity medium from 30 µl of slurry. 75 µl of 1 mg/mL 3xFLAG peptide was used for elution. ½ of the sample was saved for RNA extraction (input) and the other ½ was carried forward to split-tandem IP, using 15 µl α-ORF1 affinity medium slurry. RNAs were extracted from input, α-ORF1 supernatant fractions, as well as directly from the α-ORF1 affinity medium (elution) with 500 µl of TRIzol (Thermo Fisher Scientific \#15596026), following the manufacturer's instructions. Aqueous TRIzol extracts were re-extracted in an equal volume of chloroform, and the aqueous phase was again removed; 1 µl (\~15 ug) of GlycoBlue (Thermo Fisher Scientific \#AM9516) and 2 ul of RNasin were added to this and mixed before combining with 250 µl of isopropanol and incubating for 10' on ice to precipitate RNA. Alcohol precipitates were centrifuged at 20 k RCF for 30' @ 4°C and the pellets were washed twice with 500 µl of cold 70% ethanol, then air dried for 5' at RT and re-solubilized in 100 µl of nuclease-free water. Extracted RNAs in water were then further purified and concentrated using a Qiagen RNeasy MinElute Cleanup Kit (\#74204) following the manufacturer's instructions, and eluted in 14 µl of nuclease-free water. 5 µl of purified RNA was used directly in RNA fragmentation. Libraries were prepared with unique barcodes and were pooled at equimolar ratios. The pool was denatured and sequenced on Illumina NextSeq 500 sequencer using high output V2 reagents and NextSeq Control Software v1.4 to generate 75 bp single reads, following manufacturer's protocols (\#15048776, Rev.E).

RNA sequencing data analysis {#s4-8}
----------------------------

Human genome hg19 GRCh37.87 (FASTA) and annotation (GTF file) were downloaded from ENSEMBL (<ftp://ftp.ensembl.org/pub/grch37/release-90>) and reference FASTA and GTF files were created by combining the human genome and *ORFeus*-Hs from pLD401 ([@bib96]); [Supplementary file 7](#supp7){ref-type="supplementary-material"}: ORFeus-Hs_pLD401.gbk). To map sequencing reads onto the reference genome and produce differential gene expression analysis: (1) FASTAQ files were trimmed via trimmomatic ([@bib11]) using the following parameters: -phred33 -threads 8, LEADING:3 TRAILING:3 SLIDINGWINDOW:4:16 MINLEN:25; (2) mapping was performed via STAR ([@bib24]) version 2.5.3a (<https://github.com/alexdobin/STAR>) using the following parameters: -runThreadN 8, \--quantMode GeneCounts, \--outSAMtype BAM SortedByCoordinate, \--outFilterMatchNmin 30; (3) the results were output to one binary alignment map file for each sample matched to the reference; (4) genes with the coverage of 10 or more reads in at least three experiments were selected; and (5) data was normalized using the 'DESeq2' ([@bib62]) R package version 1.14.1. Raw and normalized mapped, annotated reads are described in [Supplementary file 4](#supp4){ref-type="supplementary-material"}. FASTAQ files are available through Gene Expression Omnibus at NCBI: GSE108270.

L1 element amplification protocol (LEAP) {#s4-9}
----------------------------------------

We generated an N-terminally acetylated, C-terminally amidated version of the ORF1p peptide (MENDFDELRE) as a di-peptide composed of repeats of the same sequence linked by a four-unit polyethylene glycol moiety; which was used to elute ORF1p-containing complexes from α-ORF1p medium at a concentration of approximately 2 mM (Appendix 1; [Supplementary file 4](#supp4){ref-type="supplementary-material"}). Peptides were synthesized by standard Fmoc solid-phase synthesis methods ([@bib48]); the incorporation of a PEG spacer into the peptide sequence was accomplished using N-Fmoc-amido-(PEG) n-acid building blocks. 400 mg of cryogenically milled L1-expressing cells (pLD401 and pLD561) were subjected to split-tandem affinity capture as described above, but with native elution from α-ORF1p medium and included the addition of RNasin (Promega \#N2515) at 1:500 v/v to the extraction buffer; 1x protease inhibitors and 1:200 v/v RNasin were also added to the 3xFLAG peptide and ORF1p-derived di-peptide solutions. For α-FLAG affinity capture, competitive elution was achieved using 60 μl of 1 mg/ml 3xFLAG peptide. Of this, 20 μl were held aside (Input), 40 μl were carried forward to α-ORF1p affinity capture. The ORF1p-depleted fraction was retained (Sup) and the captured material was eluted with 40 μl ORF1p di-peptide (Elu). Half of each fraction (Input, Sup, Elu) was set aside for protein analysis ([Supplementary file 4](#supp4){ref-type="supplementary-material"}) and to the other half, glycerol was added to 25% v/v (using a 50% v/v glycerol solution); the latter were subsequently analyzed for enzymatic activity by LEAP. Raw data resulting from these assays is located in [Supplementary file 4](#supp4){ref-type="supplementary-material"}. For LEAP, 2 μl from each of the above-described fractions were used in a 50 μl reaction, and 1 μl of each LEAP assay was used in SYBR Green qPCR (carried out in triplicate) as previously described ([@bib96]). As controls, (1) an untagged L1RP construct was used in a 'mock purification,' and (2) pLD401-derived 'Input' was heated at 100°C for 5 min and then added to the reaction mix, respectively. Neither produced detectable activity ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). A second LEAP analysis was later carried out on an independently prepared set of fractions, prepared as above, stored frozen −80°C in 25% v/v glycerol.

ORF protein immunofluorescence analysis in HeLa cells {#s4-10}
-----------------------------------------------------

Tet-on HeLa M2 cells ([@bib41]) (a gift from Gerald Schumann), were transfected and selected with 1 µg/ml puromycin for three days. Puromycin-resistant cells were plated on coverslips pre-coated for 1--2 hr with 10 µg/ml fibronectin in PBS (Life Technologies). 8--16 hr after plating, L1 was induced with 1 µg/ml doxycycline. 24 hr later, cells were fixed in 3% paraformaldehyde for 10 min. Fixative was then quenched using PBS containing 10 mM glycine and 0.2% w/v sodium azide (PBS/gly). The cells were permeabilized for 3 min in 0.5% Triton X-100 and washed twice with PBS/gly. Staining with primary and secondary antibodies was done for 20 min at room temperature by inverting coverslips onto Parafilm containing 45 ml drops of PBS/gly supplemented with 1% BSA, mouse α-FLAG M2 (Sigma, 1:500), rabbit α-ORF1 JH73 (1:4000) ([@bib96]), Alexa Fluor 488 conjugated α-mouse IgG (Life Technologies, 1:1000), and Alexa Fluor 568 conjugated α-rabbit IgG (Life Technologies, 1:1000). DNA was stained prior to imaging with Hoechst 33285 (Life Technologies, 0.1 µg/ml). Epifluorescent images were collected using an Axioscop microscope (Zeiss, Jena, Germany) equipped for epifluorescence using an ORCA-03G CCD camera (Hamamatsu, Japan).

ORF2p+ nuclei proximity analysis {#s4-11}
--------------------------------

For each microscope field, nuclei were identified and spatially located using a custom script in ImageJ, consisting of Otsu thresholding and watershed transformation of DAPI signal to segment each of the nuclei. ORF2p positive nuclei were differentiated from ORF2p negative nuclei by using another thresholding script for the ORF2p fluorescence channel and cross-registering the associated nuclei; all ORF2p positive nuclei were then hand-verified and then coordinates were converted into microns. The number of ORF2p+ nuclei per field, x, and a corresponding random distribution of x nuclei was calculated by randomly and repeatedly (n = 1000) selecting x nuclei among all nuclei. The random distribution was used to calculate Bonferroni corrected p-values for the pairwise distances between ORF2p+ nuclei. The distribution of ORF2p+ inter nuclei distances was then compared to the distribution of random inter-nuclei distances using Welch's t-test. The custom scripts used to select nuclei and calculate statistics, extracted data, calculated distances, p-values, and raw images are presented in the supplement ([Supplementary file 5](#supp5){ref-type="supplementary-material"}; [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}).
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Major datasets {#s15}
--------------

The following datasets were generated:

John LaCava2017Dissection of affinity captured LINE-1 macromolecular complexes<http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD008542>Publicly available at ProteomeXchange (accession no: PXD008542)

John LaCava2017RNAs associated with affinity captured LINE-1 ribonucleoproteins<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108270>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE108270)

 {#s7}

10.7554/eLife.30094.021

All normalized affinity values, derived from H/(H + L) and L/(H + L) isotopic ratios, can be found in [Supplementary file 1](#supp1){ref-type="supplementary-material"} on the appropriate sheet; pre-normalization values are located on the sheets named 'Integration' and 'Raw.'

Modified SILAC strategy {#s7-1}
-----------------------

![SILAC suspension expression of L1 constructs: western blotting.](elife-30094-app1-fig1){#app1fig1}

### SILAC suspension expression of L1 constructs {#s7-1-1}

Western blotting of cells grown in adherent culture with puromycin selection (A) or suspension culture with transient transfection (S). Cells were grown in heavy isotope-supplemented media (^13^C ^15^N lysine and arginine) (H), light isotope-supplemented media (L) or conventional commercial media (C) supplemented with tetracycline-free serum and L-glutamine. Note that serum used for heavy and light growth is dialyzed to remove amino acids. Construct LD401: synthetic ORFeus-HS, full L1 coding sequence (both ORFs and 3'UTR) with ORF2-3xFlag. Construct LD561: identical except for the absence of ORF1.

RNase sensitivity affinity capture {#s7-2}
----------------------------------

### Data normalization {#s7-2-1}

The RNase sensitivity data were rescaled and normalized such that proteins that did not change upon treatment with RNases were centered at the origin and those that were completely sensitive would give a value of 1.0. In a perfect experiment, unchanging proteins would yield a ratio of 0.5 when comparing the fraction of each protein present in the BSA-treated sample to the sum of both the BSA- and RNase-treated samples; i.e. 1 / (1 + 1). However, our data show some variability (below, left and also [Supplementary file 1](#supp1){ref-type="supplementary-material"}), with one replicate centering on \~0.4 (red) and another \~0.6 (blue). Therefore, we normalized the data such that the peaks at \~0.4 and\~0.6 were both re-centered at 0.5. From this set, 0.5 was subtracted from the data (centering insensitive proteins at the origin, and completely sensitive proteins at 0.5), followed by multiplication by two to expand the data to cover the range from 0 (insensitive) to 1 (completely sensitive); depicted below, right. These latter two transformations are encompassed by the functions: g(x)=x + b \[where b = −0.5\] and f(g(x))=a(x + b) \[where a = 2\].

![RNase sensitivity affinity capture: data normalization.](elife-30094-app1-fig2){#app1fig2}

### RNase normality test {#s7-2-2}

The distances from the (0,0) point to protein coordinates were calculated. Proteins with distance less than two median distances were selected. The Shapiro-Wilk normality test (the null-hypothesis of this test is that the population is normally distributed) was applied for the distances (p-value=0.29). The distribution of the distances was plotted as a histogram displaying the frequency (y-axis) versus RNase sensitivity (x-axis) of a simulation of normally distributed data (shown in black) and the actual data ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) shown in blue. A Q-Q plot was also drawn.

![RNase sensitivity affinity capture: normality test.](elife-30094-app1-fig3){#app1fig3}

Split-tandem affinity capture {#s7-3}
-----------------------------

### Data normalization {#s7-3-1}

The data were treated as follows: a and b coefficients were calculated as solutions of [equation 1](#equ1){ref-type="disp-formula"}; the normalized values were calculated using the [equation 2](#equ2){ref-type="disp-formula"}.$$\begin{pmatrix}
a \\
b \\
\end{pmatrix}\begin{pmatrix}
{median} & 1 \\
{ORF1} & 1 \\
\end{pmatrix} = \begin{pmatrix}
{median} \\
1 \\
\end{pmatrix}$$$$x_{normalized} = {(a^{\ast}x_{initial}) + b}$$

![Split-tandem affinity capture: data normalization.](elife-30094-app1-fig4){#app1fig4}

### Calculate the distances between node pairs {#s7-3-2}

Distance between two points A and B with coordinates (A~x~, A~y~) and (B~x~, B~y~) was calculated as: $\sqrt{\left( \mathbf{A}_{\mathbf{x}} - \mathbf{B}_{\mathbf{x}} \right)^{2} + \mathbf{}\left( \mathbf{A}_{\mathbf{y}} - \mathbf{B}_{\mathbf{y}} \right)^{2}}$

For each three points, the mean paired distance was calculated. The distributions of mean values are presented in the histograms below.

![Distances between two-node groups.](elife-30094-app1-fig5){#app1fig5}

![Distances between three-node groups.](elife-30094-app1-fig6){#app1fig6}

### Associated likelihoods of selected clusters {#s7-3-3}

Here, likelihood is defined as the frequency with which the same mean distance or less is observed within the distribution of clusters with the same number of nodes (above).

PURA/PURB/PCNA: Likelihood = 3.2 × 10^−7^

PABPC1/PABPC4: Likelihood = 0.0008388427

HSPA8/HSPA1A: Likelihood = 0.0001991309

NAP1L1/IPO7: Likelihood = 0.0075885198

Efficacy elution from α-ORF1 4H1 affinity medium using ORF1p peptides {#s7-4}
---------------------------------------------------------------------

![Efficacy of elution using ORF1p peptides: Coomassie blue stained gel .](elife-30094-app1-fig7){#app1fig7}

ORF1p-FLAG was purified from 25 mg of cryo-milled HEK-293T~LD~ expressing pLD288 using α-ORF1 affinity medium, essentially as previously described ([@bib96]), and then eluted either eluted directly with 15 μl of 1x LDS, 70°C for 5 min (Ctrl LDS), with 2 mM monomeric ORF1 peptide (Mono pep), or 2 mM dimeric ORF1 peptide (Di pep) (in both cases for 15 min at room temperature). After elution with peptide, the affinity medium was further eluted with 1x LDS at 70°C for 5 min (Mono and Di LDS, respectively).

Retrotransposition mutants affinity capture {#s7-5}
-------------------------------------------

The distributions of normalized affinities for the two sets of experiments are shown below.

![Retrotransposition mutants affinity capture: distributions of normalized affinities.](elife-30094-app1-fig8){#app1fig8}

Protein in vitro exchange {#s7-6}
-------------------------

The distributions of H/(H + L) values present at each time point are shown.

![Protein in vitro exchange: the distributions of H/(H+L) values.](elife-30094-app1-fig9){#app1fig9}

Affinity capture of ORF2p-3xFLAG L1 from fractionated chromatin and MS analyses {#s7-7}
-------------------------------------------------------------------------------

### Cell culture {#s7-7-1}

Briefly, suspension grown HEK-293TLD cells were seeded at 1 × 106 cells/ml in 100 ml of medium and transfected with pLD401 (ORF2p-3xFLAG L1 construct) or pLD259 (untagged L1 control construct) plasmid DNA. The transfection mixture consisted of Hybridoma serum free media (1/20 of final volume), PEI (3 μg/ml final volume) and plasmid DNA (1 μg/ml final volume). The mixture was incubated for 15 min at room temperature before adding to cell suspension. 24 hr post transfection, cells were split 1:3 into 1 μg/ml puromycin media. Expression was induced 48 hr post transfection by the addition of doxycycline (1 μg/ml) and maintained for 48 hr before collection for chromatin fractionation. A total of 900 ml final cell suspension per construct (≈3 × 106 cells/ml) were prepared as follows.

### Chromatin fractionation {#s7-7-2}

Cell suspensions were centrifuged at 200 RCF for 10 min and washed with 20 ml PBS. Cell pellets were resuspended in 5 ml of Buffer A (100 mM HEPES, 1.5 mM MgCl2, 0.34 M sucrose, 10% (v/v) glycerol; with 1 mM DTT and protease inhibitors freshly added). Triton X-100 was added to 0.1% (v/v) final concentration and cells were allowed to swell on ice for 10 min. Nuclei were pelleted for 5 min at 1300 RCF, 4°C and the supernatant (cytoplasmic fraction) was discarded. Nuclei were resuspended in 2.5 ml Buffer B (3 mM EDTA, 0.2 mM EGTA; with 1 mM DTT and protease inhibitors freshly added) and incubated on ice for 30 min before centrifuging at 1700 RCF for 5 min. The soluble nuclear fraction was discarded and the insoluble material was washed twice with Buffer B. The remaining chromatin fraction was resuspended in 5 ml MNase buffer (a Tris buffered 10 mM KCl, 1 mM CaCl2 solution) supplemented with 5 U/ml micrococcal nuclease and incubated at 37°C for 5 min with agitation. The reaction was quenched by adding EGTA to 1 mM final concentration and incubating for 2 min. The solution was centrifuged for 5 min at max speed and supernatant (chromatin fraction) transferred to a fresh tube.

### Immunoprecipitation {#s7-7-3}

The chromatin fractions were normalized by Bradford Assay and equal amounts of proteins were used for the IP. The chromatin fractions were diluted in concentrated buffer to a final concentration of 500 mM NaCl, 20 mM HEPES, pH 7.4, and 1% (v/v) Triton X-100 (same formula used as washing buffer, below). 50 μl of magnetic beads (Life Technologies 14311D) conjugated to FLAG-M2 antibody (Sigma F1804) were added to the fractions incubated for 1 hr at 4°C under end-over-end rotation. The affinity media were washed 10 times with washing and twice with 500 mM NaCl, 20 mM HEPES, pH 7.4, and 0.1% (v/v) Triton X-100. Proteins were eluted for 30 min at room temperature under continuous shaking in 50 μl of 1 mg/ml 3xFLAG peptide (Sigma F4799) diluted in washing buffer with 0.1% Triton X-100. The eluates were collected and combined with NuPAGE 4x LDS Sample Buffer (Novex) to a final concentration of 1x.

### Preparation for mass spectrometry {#s7-7-4}

The samples were reduced with 2 μl of 0.2M dithiothreitol (Sigma) for one hour at 57°C at pH 8.0. Next the samples were alkylated with 2 μl of 0.5M iodoacetamide (Sigma) for 45 min at room temperature in the dark. The samples were loaded on a NuPAGE 4--12% Bis-Tris Gel 1.0 mm (Life Technologies) and run for 6 min at 200V. The gel was stained with GelCode Blue Stain Reagent (Thermo). The gel plugs were excised and destained for 15 min in a 1:1 (v/v) solution of methanol and 100 mM ammonium bicarbonate. The buffer was exchanged and the samples were destained for another 15 min. This was repeated for another three cycles. The gel plugs were dehydrated by washing with acetonitrile, and then further dried by placing in a SpeedVac for 20 min. The gel plugs were treated with 250 ng of sequencing grade modified trypsin (Promega) by adding directly on top of the dried gel plugs, and then enough 100 mM ammonium bicarbonate was added in order to cover the gel pieces. The gel plugs were allowed to shake at room temperature and digestion proceeded overnight. The digestion was halted by adding a slurry of R2 50 μm Poros beads (Applied Biosystems) in 5% formic acid and 0.2% trifluoroacetic acid (TFA) to each sample at a volume equal to that of the ammonium bicarbonate added for digestion. The samples were allowed to shake at 4⁰C for three hours. The beads were loaded onto C18 ziptips (Millipore), equilibrated with 0.1% TFA, using a microcentrifuge for 30 s at 6,000 rpm. The beads were washed with 0.5% acetic acid. Peptides were eluted with 40% acetonitrile in 0.5% acetic acid followed by 80% acetonitrile in 0.5% acetic acid. The organic solvent was removed using a SpeedVac concentrator and the sample reconstituted in 0.5% acetic acid.

### Mass spectrometry analysis -- Thermo Orbitrap Elite instrument {#s7-7-5}

An aliquot of each sample was loaded onto an Acclaim PepMap100 C18 75 μm x 15 cm column with 3 μm bead size, coupled to an EASY-Spray 75 μm x 50 cm PepMap C18 analytical HPLC column with a 2 μm bead size, using the auto sampler of an EASY-nLC 1000 HPLC (ThermoFisher) and solvent A (2% acetonitrile, 0.5% acetic acid). The peptides were eluted into a ThermoFisher Scientific Orbitrap Elite Hybrid Ion Trap Mass Spectrometer increasing from 2% to 30% solvent B (90% acetonitrile, 0.5% acetic acid) over 60 min, followed by an increase from 30% to 40% solvent B over 30 min. Solvent B was then put to 100% and held at 100% for 20 min. High resolution full MS spectra were obtained with a resolution of 60,000 at 400 m/z, an AGC target of 1e6, with a maximum ion time of 200 ms, and a scan range from 300 to 1500 m/z. Following each full MS scan, fifteen data-dependent MS/MS spectra were acquired. The MS/MS spectra were collected in the ion trap, with an AGC target of 1e4, maximum ion time of 150 ms, one microscan, 2 m/z isolation window, fixed first mass of 150 m/z, and Normalized Collision Energy (NCE) of 35.

### Mass spectrometry analysis -- Thermo Fusion instrument {#s7-7-6}

An aliquot of each sample was loaded onto an Acclaim PepMap100 C18 75 μm x 15 cm column with 3 μm bead size, coupled to an EASY-Spray 75 μm x 50 cm PepMap C18 analytical HPLC column with a 2 μm bead size, using the auto sampler of an EASY-nLC 1000 HPLC (ThermoFisher) and solvent A (2% acetonitrile, 0.5% acetic acid). The peptides were eluted into a ThermoFisher Scientific Orbitrap Fusion Mass Spectrometer increasing from 2% to 30% solvent B (90% acetonitrile, 0.5% acetic acid) over 60 min, followed by an increase from 30% to 40% solvent B over 30 min. Solvent B was then put to 100% and held at 100% for 20 min. High resolution full MS spectra were obtained with a resolution of 120,000, an AGC target of 400,000, with a maximum ion time of 50 ms, and a scan range from 400 to 1500 m/z. The MS/MS spectra were collected in the ion trap, with an AGC target of 100, maximum ion time of 250 ms, one microscan, 2 m/z isolation window, fixed first mass of 150 m/z, and Normalized Collision Energy (NCE) of 27.

### Data processing {#s7-7-7}

All acquired MS2 spectra were searched against a UniProt human database using Sequest within Proteome Discoverer (ThermoScientific). The search parameters were as follows: precursor mass tolerance ±10 ppm, fragment mass tolerance ±0.4 Da, digestion parameters allowing trypsin two missed cleavages, fixed modification of carbamidomethyl on cysteine, variable modification of oxidation on methionine, and variable modification of deamidation on glutamine and asparagine. The results were filtered to only include proteins identified by at least two peptides.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Dissection of purified LINE-1 reveals distinct nuclear and cytoplasmic intermediates\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and James Manley as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Geoffrey Faulkner (Reviewer \#2); Victoria Belancio (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This paper reports the protein content of LINE-1 complexes in the cytoplasm and nucleus of cells undergoing retrotransposition events, and uncovers an array of distinctive complexes. The reviewers uniformly found the story to be of much interest and to constitute a significant advance beyond published work. They are enthusiastic.

We include all their reviews here for consideration. There were raised many shared issues of what were judged to be overinterpretations or overstatements of the data. I think most of the comments can be addressed by rewriting.

A common thread is the point that we cannot know whether the complexes are on a direct pathway to retrotransposition, or whether they are even on a pathway at all. Some disclaimers here are needed.

Essential revisions:

*Reviewer 1:*

The point about Orf2 traversing the RNA in the cytoplasm, given what we think we know about the process of RT here, seems cogent. Here it is probably correct that the data do not rule out the presence of Orf1 in the nucleus at the time of RT. This needs to be addressed.

*Reviewer 2:*

There are real issues about the cell localization data. We should not assume that the localization of cellular proteins is according to the dogma in non-transposing cells, outside of the Orf complexes. There are real issues about IF quantification that need to be addressed.

*Reviewer 3:*

Almost all the comments here are valid and readily addressed. Again, the issue of Orf1 in the nucleus is raised as a red flag that needs to be addressed, likely by softening of claims.

We look forward to receiving a revised version with a point-by-point response to the reviews.

*Reviewer \#1:*

This study provides a significant advance in our understanding of biochemical interactions of LINE-1 encoded proteins, with solid evidence for multiple, varied interactions with distinct host cell components in both the nucleus and the cytoplasm. The authors employ sophisticated, quantitative methods to interrogate protein interactions of (primarily) the LINE-1 ORF2 protein, thereby gaining new insight into the complexity of the host-parasite relationship and process of LINE-1 retrotransposition. It represents a significant step forward for the field, building on results of Taylor published in 2013 in Cell. There are however some issues with the wording of some conclusions overstepping the limits of what is documented by the data presented, as specifically noted below. With wording changes to more accurately describe/interpret the data the most serious limitation of this work (the lack of a co-analysis of the L1 nucleic acid intermediates), could be considered minor.

In Abstract \"our findings support the presence of multiple L1-derived retrotransposition intermediates in vivo\"; oversteps the actual data because there is no direct evidence to address which of these various complexes are bona fide retrotransposition intermediates vs which reflect the various ways the cell interferes with/prevents retrotransposition.

In numerous instances the term \"purified\" is used when the data support \"enrichment\" but not purification. This leads to confusion when the \"purified\" complex turns out to be, as is the point of the work, multiple distinct complexes.

The conclusion \"\[...\]ORF1p probably does not interact with ORF2p in the nucleus\", is not supported by the data, which simply show that there are RNA- and ORF1p-independent interactions between ORF2p and non-L1 cellular proteins in the nucleus. Agreed that the data show a persistent complex of ORF2p that lacks ORF1p, but that is not the same as the above. There is likewise no data to support \"ORF1p may be displaced from the L1 RNA during the nuclear portion of the lifecycle\" -- maybe there is also no remaining L1 RNA by the time the ORF2 complexes lacking ORF1p are formed. The authors should provide supporting data to support this claim or remove it.

Subsection "4.4. The effects of retrotransposition-blocking point mutations on the interactomes of purified L1 RNPs". TPRT is target primed reverse transcription, not \"template\".

Subsection "4.4. The effects of retrotransposition-blocking point mutations on the interactomes of purified L1 RNPs". What evidence suggests that ORF2 traverses L1 RNA in cytoplasm? Given that this RT gets its primer from the target DNA this comment seems unwarranted. This unnecessary speculation is not appropriate for the Results section. In fact the effects of the RT and EN mutations are actually so subtle (\~2x) compared to the robust effects they have on retrotransposition (\>\>100X) it may speak more to the fact that neither of these most abundant L1-containing protein complexes (both nuclear and cytoplasmic) are on the productive retrotransposition pathway.

[Figure 6](#fig6){ref-type="fig"} model -- there is no evidence linking the L1 RNA to this nuclear complex with ORF2p and without ORF1p. Given that ORF1p is required to get ORF2p into the nucleus, that some ORF1p does get to the nucleus and in a form that is somehow unique (based on different reactivity of the various antibodies), and that 25% of the ORF2p follows ORF1p in the sequential enrichments, an important role for ORF1p in the nucleus seems highly likely. It would be reasonable from the data presented to consider at least two nuclear forms with ORF2p containing complexes, one with the L1 RNA and ORF1p and one without these other L1 components but with the other nuclear components.

*Reviewer \#2:*

Molloy et al. perform affinity purifications followed by quantitative mass spectrometry to identify proteins that interact with the L1-encoded proteins and mRNA in ribonucleoprotein particles (RNPs). Their results suggest the existence of multiple different L1 RNPs that contain the L1-encoded proteins ORF1p and ORF2p and various cellular factors at distinct stoichiometries and in discrete subcellular locations. The major advance of this manuscript over the work of Taylor et al. (Cell, 2013) is the resolution of the subcellular localisation of the different RNP intermediates. These data are really interesting and should be the starting point for a range of follow-up investigations. However, the strength with which some of the conclusions are presented is not sufficiently justified by the available data and this should be addressed prior to publication.

1\) Most of the conclusions about the subcellular localisation of ORF1p/ORF2p versus ORF2p-only RNP complexes are drawn from the known subcellular localisation and ontological classification of their interacting protein partners. While these data are interesting, the paper would be greatly improved by the direct demonstration of differential subcellular colocalisation of the L1 proteins with their interacting partners. Indeed, the experiments aimed at verifying these conclusions are not entirely convincing, and in some cases the results are overstated or overgeneralised (see below).

2\) The authors performed ORF2p-3XFLAG affinity capture from chromatin-enriched subcellular fractions to support the conclusion that ORF2p-only RNPs localise to the nucleus. The text states that proteins co-purifying with chromatin-associated ORF2p \"largely overlapped\" with those described as nuclear ORF2p-only RNP interactors. However, comparing the list of these proteins in [Supplementary file 3](#supp3){ref-type="supplementary-material"} to the list of ORF2-only interactors in [Table 1](#table1){ref-type="table"} reveals relatively little overlap. [Table 1](#table1){ref-type="table"} contains 21 ORF2p-only interactors and Table S3 contains 15 nuclear ORF2p interactors, yet only five factors (PARP1, IPO7, PCNA, PURA, and TOP1) are actually shared by both lists. The statement that the lists \"largely overlapped\" needs to be softened, and the extent of the overlap explicitly stated in the text.

3\) Immunofluorescence experiments have little quantitative information. Statements like \"these cells accounted for \<10% of the population\" and \"Expression of ORF2p in the absence of ORF1p resulted in \>90% of cells exhibiting cytoplasmic ORF2p\" and \"they always occurred in proximal pairs\" would be much more convincing with some statistical information about the experiment. How many cells were analysed? How many times were the results replicated? Clarity here would bolster the results.

4\) Immunofluorescence experiments could also be used to demonstrate colocalisation of ORF1p and ORF2p with their presumed interaction partners in the cytoplasm and nucleus, and would provide more direct support for the conclusions drawn regarding subcellular localisation of different L1 RNPs. Such experiments would understandably be limited by the availability of antibodies to the interacting factors, but would almost certainly be feasible in some cases.

5\) Analysis of host factors differentially associated with RT and EN mutant L1 RNPs is also intriguing, but the results are over-interpreted. As a whole, most of the conclusions drawn in the manuscript need to be backed up by more direct functional assays, or the language in which the conclusions are stated needs to be softened considerably.

*Reviewer \#3:*

This is an experimentally sound, well-written manuscript demonstrating the existence of distinct L1 complexes with potentially different roles in L1 retrotransposition. The results presented in this manuscript are novel and provide significant insights into L1 RNPs and its role in the L1 replication cycle. In addition to identifying L1 interactors with a previously reported role in L1 retrotransposition, the authors provide experimental validation of additional and previously unknown interactors. Another important finding is the demonstration that the proportions of proteins within L1 complexes is affected by individual mutations of the L1 ORF2p catalytic activities. I am very enthusiastic about the findings described in this manuscript. I think they significantly advance the research related to transposable elements and viruses and would be helpful to the future progress of studies conducted by other labs.

This reviewer did not have access to the co-submitted manuscript by Mita et al.

• Indicate if the status of L1ORFeus mRNA in the different fractions shown in [Figure 1D](#fig1){ref-type="fig"}.

• Subsection "4.2. Split-tandem separation of compartment-specific L1 ORF-associated complexes", the last paragraph provides experimental validation of the significant overlap between putative nuclear L1 complexes and complexes detected in chromatic enriched fractions. Please discuss this validation earlier in this study as it provides important experimental support for the references to these complexes as nuclear.

• Comment on how these nuclear and cytoplasmic complexes align with the existing literature showing that L1 RT present in the cytoplasm generates cDNA when provided with a primer (LEAP protocol).

• \"We did not observe instances of nuclear ORF2p using the construct ([Figure 2](#fig2){ref-type="fig"}, bottom row), suggesting that ORF1p is required for ORF2p nuclear localization.\" This statement needs to be put in the context of published data demonstrating that the ORF2p expressing plasmids support efficient Alu retrotransposition.

• In [Figure 5](#fig5){ref-type="fig"}, the distance is presented \"on a one-unit arbitrary scale.\" Provide more information on how this unit was developed.

• The model in [Figure 6](#fig6){ref-type="fig"} and several statements throughout the manuscript indicate a complete lack of specific proteins in the nuclear and cytoplasmic complexes. Please clarify if this is an accurate interpretation. Are some proteins enriched in specific complexes and depleted in others rather than absent?

• Statements that are supported by unpublished data that are not shown in this or the accompanying manuscript should be eliminated or restated.

• Discuss the possibility that the lack of detection of the L1 ORF1p in the nucleus by IHC could be due to technical problems rather than the lack of the protein?

10.7554/eLife.30094.037

Author response

> Reviewer \#1:
>
> This study provides a significant advance in our understanding of biochemical interactions of LINE-1 encoded proteins, with solid evidence for multiple, varied interactions with distinct host cell components in both the nucleus and the cytoplasm. The authors employ sophisticated, quantitative methods to interrogate protein interactions of (primarily) the LINE-1 ORF2 protein, thereby gaining new insight into the complexity of the host-parasite relationship and process of LINE-1 retrotransposition. It represents a significant step forward for the field, building on results of Taylor published in 2013 in Cell. There are however some issues with the wording of some conclusions overstepping the limits of what is documented by the data presented, as specifically noted below. With wording changes to more accurately describe/interpret the data the most serious limitation of this work (the lack of a co-analysis of the L1 nucleic acid intermediates), could be considered minor.

We added LEAP and RNA-seq experiments in order to account for the state of the L1 RNA (and RNA generally) across various fractions -- now presented in new [Figure 2](#fig2){ref-type="fig"}, and updated [Figure 4](#fig4){ref-type="fig"}.

> In Abstract \"our findings support the presence of multiple L1-derived retrotransposition intermediates in vivo\"; oversteps the actual data because there is no direct evidence to address which of these various complexes are bona fide retrotransposition intermediates vs which reflect the various ways the cell interferes with/prevents retrotransposition.

We agree that the diversity of putative assemblies are of unknown molecular physiology (and that their ultimate outcome is unknown), and accordingly, more nuance is required to avoid over-lumping and over-interpretation. We amended the text and title. In numerous places we substituted e.g. "L1 macromolecules" and "protein complexes" in place of "intermediates." A few instances of "intermediate" were retained where it seemed appropriate for the concept being conveyed. We have also shown the preps to be enzymatically active by LEAP assay (new [Figure 2](#fig2){ref-type="fig"}).

> In numerous instances the term \"purified\" is used when the data support \"enrichment\" but not purification. This leads to confusion when the \"purified\" complex turns out to be, as is the point of the work, multiple distinct complexes.

Agreed: we have modified numerous instances of "purified," with alternative descriptors such as "enriched" and "affinity captured."

> The conclusion \"\[...\]ORF1p probably does not interact with ORF2p in the nucleus\", is not supported by the data, which simply show that there are RNA- and ORF1p-independent interactions between ORF2p and non-L1 cellular proteins in the nucleus. Agreed that the data show a persistent complex of ORF2p that lacks ORF1p, but that is not the same as the above. There is likewise no data to support \"ORF1p may be displaced from the L1 RNA during the nuclear portion of the lifecycle\" -- maybe there is also no remaining L1 RNA by the time the ORF2 complexes lacking ORF1p are formed. The authors should provide supporting data to support this claim or remove it.

We removed the text "ORF1p probably does not interact with ORF2p in the nucleus\" and "ORF1p may be displaced from the L1 RNA during the nuclear portion of the lifecycle."

> Subsection "4.4. The effects of retrotransposition-blocking point mutations on the interactomes of purified L1 RNPs". TPRT is target primed reverse transcription, not \"template\".

Fixed.

> Subsection "4.4. The effects of retrotransposition-blocking point mutations on the interactomes of purified L1 RNPs". What evidence suggests that ORF2 traverses L1 RNA in cytoplasm? Given that this RT gets its primer from the target DNA this comment seems unwarranted. This unnecessary speculation is not appropriate for the Results section. In fact the effects of the RT and EN mutations are actually so subtle (\~2x) compared to the robust effects they have on retrotransposition (\>\>100X) it may speak more to the fact that neither of these most abundant L1-containing protein complexes (both nuclear and cytoplasmic) are on the productive retrotransposition pathway.

We removed the speculative text pertaining to ORF2p traversing L1 RNA in cytoplasm.

> [Figure 6](#fig6){ref-type="fig"} model -- there is no evidence linking the L1 RNA to this nuclear complex with ORF2p and without ORF1p. Given that ORF1p is required to get ORF2p into the nucleus, that some ORF1p does get to the nucleus and in a form that is somehow unique (based on different reactivity of the various antibodies), and that 25% of the ORF2p follows ORF1p in the sequential enrichments, an important role for ORF1p in the nucleus seems highly likely. It would be reasonable from the data presented to consider at least two nuclear forms with ORF2p containing complexes, one with the L1 RNA and ORF1p and one without these other L1 components but with the other nuclear components.

We agree that ORF1p may play a role in the nucleus, but the current data lack granularity that would allow us to define these complexes further. We note that data in the companion manuscript by Mita et al. suggest that any role of ORF1p in the nucleus is transient and show no nuclear co-localization between ORF1p and ORF2p. Accordingly we have modified the figure to show both RNA-linked and non-linked ORF1p in the nucleus, with a semi-transparent shade to imply our lack of knowledge regarding these interactions (now [Figure 7](#fig7){ref-type="fig"}).

We now provide two lines of evidence supporting the presence of the L1 RNA in the ORF2p-containing nuclear complex lacking ORF1p: (1) high levels of LEAP activity and (2) RNA sequencing data. We respectfully disagree, therefore, that the ORF1p-lacking complex should also lack the L1 RNA. The remaining schematic accordingly shows ORF2p as the protein interaction hub, in keeping with our lack of evidence to support RNA as a key player in those interactions. We note additionally that the presumed mechanism of L1 insertion, TPRT, would require an ORF2p-L1 RNA interaction at the chromatin. Disruption of e.g. PCNA and UPF1 interactions with ORF2p have strong negative effects on retrotransposition; mild positive effects were observed when knocking down TOP1 and PURA/B; we also identified most of these proteins in ORF2p affinity captured from fractionated chromatin. We conclude that these ORF2p interactions modulate retrotransposition and very likely occur at the chromatin.

> Reviewer \#2:
>
> \[...\] 1) Most of the conclusions about the subcellular localisation of ORF1p/ORF2p versus ORF2p-only RNP complexes are drawn from the known subcellular localisation and ontological classification of their interacting protein partners. While these data are interesting, the paper would be greatly improved by the direct demonstration of differential subcellular colocalisation of the L1 proteins with their interacting partners. Indeed, the experiments aimed at verifying these conclusions are not entirely convincing, and in some cases the results are overstated or overgeneralised (see below).
>
> 2\) The authors performed ORF2p-3XFLAG affinity capture from chromatin-enriched subcellular fractions to support the conclusion that ORF2p-only RNPs localise to the nucleus. The text states that proteins co-purifying with chromatin-associated ORF2p \"largely overlapped\" with those described as nuclear ORF2p-only RNP interactors. However, comparing the list of these proteins in [Supplementary file 3](#supp3){ref-type="supplementary-material"} to the list of ORF2-only interactors in [Table 1](#table1){ref-type="table"} reveals relatively little overlap. [Table 1](#table1){ref-type="table"} contains 21 ORF2p-only interactors and Table S3 contains 15 nuclear ORF2p interactors, yet only five factors (PARP1, IPO7, PCNA, PURA, and TOP1) are actually shared by both lists. The statement that the lists \"largely overlapped\" needs to be softened, and the extent of the overlap explicitly stated in the text.

Fixed. The overlapping proteins have been more explicitly stated in the main text, and the supplementary table has been amended to draw attention to the proteins in question. We purposefully restricted the stated overlap between the proteins identified in the two different experimental designs to those proteins meeting the conservative filter of "I-DIRT specific;" detection alone was not considered sufficient. The rationale is set out in the first two paragraphs of the Results. E.g. the proteins SSBP1, PRPF6, RBM14, U2SURP, SRSF5 (not described as overlapping) were detected in the chromatin fraction ORF2p IP as well as at least one other IP presented in this study, but we do not consider that a compelling enough case to present them as putative L1 interactors at this time. Moreover, we note that in the chromatin fraction ORF2p IP experiment presented in the supplement, of the proteins found to be enriched with ORF2p in the chromatin fraction, only PCNA was also detected after IP of ORF2p from unfractionated cell extracts -- this is a general limitation in the sensitivity and dynamic range provided by shotgun proteomic experiments -- such that it is not uncommon to observe limited overlap in different proteomic experimental regimes.

> 3\) Immunofluorescence experiments have little quantitative information. Statements like \"these cells accounted for \<10% of the population\" and \"Expression of ORF2p in the absence of ORF1p resulted in \>90% of cells exhibiting cytoplasmic ORF2p\" and \"they always occurred in proximal pairs\" would be much more convincing with some statistical information about the experiment. How many cells were analysed? How many times were the results replicated? Clarity here would bolster the results.

These images were collected a couple years ago and at the time we did not have the foresight to plan a rigorous quantitative analysis. We counted many cells we observed and estimated frequencies of subpopulations, but did not record images from the population that were not "interesting" with respect to observed ORF1p/ORF2p expression -- moreover, aside from the nuclear ORF2p cells, the results were comparable to those we previously published in Taylor et al. 2013. Unfortunately, we currently lack the personnel to revisit this experimental regime. We therefore softened our language regarding the precise proportions of the populations observed. However, to respond to the reviewer and strengthen the manuscript, we added a new companion analysis. We possess 11 such IF images displaying the described ORF2p staining phenomenon, among other non-staining cells (now provided in supplement along with the extracted/analyzed data tables). We analyzed the distributions of cell-cell proximities (nuclei) in these images to provide a quantitative validation of our claim regarding the proximity of cells displaying nuclear ORF2p -- now presented in [Figure 3](#fig3){ref-type="fig"}. We used a comparable analysis procedure to that presented by Mita et al. in the co-submitted *eLife* manuscript.

> 4\) Immunofluorescence experiments could also be used to demonstrate colocalisation of ORF1p and ORF2p with their presumed interaction partners in the cytoplasm and nucleus, and would provide more direct support for the conclusions drawn regarding subcellular localisation of different L1 RNPs. Such experiments would understandably be limited by the availability of antibodies to the interacting factors, but would almost certainly be feasible in some cases.

We do certainly agree that in some cases these experiments would be feasible and informative. As stated above, there are some expected limitations related to identifying reagents, as well as expectations that some may not generate discrete/enriched co-localization foci. E.g. as annotated in Uniprot, many have broad, diffuse, or complex localizations -- we also agree with the reviewer's point that localization of these proteins in the context of L1 expression may differ from that defined by normal conditions, curated in databases. Hence, this experiment would require some time for trial and error on our part and, given IF is not the expertise of our core-team, was not an experiment we could implement within the post-review timeframe.

We have instead softened our language throughout (in response to this and other reviewer points), in order to compensate for the reviewer's degree of skepticism regarding putative L1 complexes, and we have added additional IF co-localization as a future experimental direction in the discussion. We also believe this point is at least partly addressed by the chromatin fractionation experiment (pt. 1, above) which showed compositional overlap with our proposed nuclear L1 intermediates inferred from alternative fractionation schemes ([Figure 1](#fig1){ref-type="fig"}).

> 5\) Analysis of host factors differentially associated with RT and EN mutant L1 RNPs is also intriguing, but the results are over-interpreted. As a whole, most of the conclusions drawn in the manuscript need to be backed up by more direct functional assays, or the language in which the conclusions are stated needs to be softened considerably.

The manuscript as a whole has been modified to soften tone, including the changes made in response to reviewer \#1; in this section we removed the text pertaining to ORF2p traversing L1 RNA in cytoplasm, as well as other modifications.

> Reviewer \#3:
>
> \[...\] • Indicate if the status of L1ORFeus mRNA in the different fractions shown in [Figure 1D](#fig1){ref-type="fig"}.

RNA-seq and LEAP analysis of the fractions has now been provided, see new [Figure 2](#fig2){ref-type="fig"}.

> • Subsection "4.2. Split-tandem separation of compartment-specific L1 ORF-associated complexes", the last paragraph provides experimental validation of the significant overlap between putative nuclear L1 complexes and complexes detected in chromatic enriched fractions. Please discuss this validation earlier in this study as it provides important experimental support for the references to these complexes as nuclear.

We attempted to accommodate this critique, however, we cannot move this section to an early position in the manuscript because the section, as written, leverages the observation of TOP1 as part of the putative nuclear L1 complex. TOP1 was not detected in the RNase experiment, and therefore, moving this section requires some acrobatics to narrate the significance of the TOP1 observation and testing of TOP1 by over-expression, etc. If the reviewer is adamant on this request, we could accommodate it with a more involved re-write where we excise the text describing the chromatin fractionation and move it to the previous section, but leave the over-expression results where they are (following the observation of TOP1). We note that, as it stands, this information is provided in the Results section attached to [Figure 1](#fig1){ref-type="fig"}, so, it is provided at a reasonably early juncture.

> • Comment on how these nuclear and cytoplasmic complexes align with the existing literature showing that L1 RT present in the cytoplasm generates cDNA when provided with a primer (LEAP protocol).

We have done LEAP experiments on split-tandem affinity captured L1 fractions (those of [Figure 1D](#fig1){ref-type="fig"}), and all fractions are highly active (new [Figure 2](#fig2){ref-type="fig"}). The absolute activity between the fractions is similar (within 2-fold for LD401) but the RNA and protein partitioning is not, and thus depending on how the data is normalized (to ORF2p or the L1 RNA) the specific activity can be viewed in different ways. These experiments require further investigation and the data will require a thorough and nuanced discussion that will be included in a follow-up study we're conducting on the enzymatic activities of purified L1 macromolecules. For now, we can conclude that the RNA-ORF2p complex seems competent to perform LEAP given the appropriate primer, with or without detectable ORF1p. Further we would note that the precise subcellular localization of the active L1 RT in previously reported LEAP preparations is far from clear. Our prior work was whole cell extracts made by cryomilling; the Moran lab protocol uses roughly 3 packed cell volumes of a hypotonic buffer with 1% Triton X-100 and 1% deoxycholate detergents before ultracentrifugation and contains protein from multiple cellular compartments, along with \~65-fold less specific activity than the affinity-purified fractions. Thus at least formally, we don't know that the subcellular origin of LEAP-competent RT in these assays.

> • \"We did not observe instances of nuclear ORF2p using the construct ([Figure 2](#fig2){ref-type="fig"}, bottom row), suggesting that ORF1p is required for ORF2p nuclear localization.\" This statement needs to be put in the context of published data demonstrating that the ORF2p expressing plasmids support efficient Alu retrotransposition.

This has been addressed in the Discussion.

> • In [Figure 5](#fig5){ref-type="fig"}, the distance is presented \"on a one-unit arbitrary scale.\" Provide more information on how this unit was developed.

This is explained in the Materials and methods section: "To integrate and plot the combined data ([Figure 5](#fig5){ref-type="fig"} -- now [Figure 6](#fig6){ref-type="fig"}), we calculated Euclidean and cosine distances for each I-DIRT-significant protein pair present in each experiment. Euclidean distances were rescaled to the range (0, 0.9). Proteins not detected in any common experiments were assigned a Euclidian distance of 1 after rescaling. The total distance between protein pairs was calculated as d = log((rescaled Euclidean distance) \* (cosine distance)). This distance was rescaled to the range (0, 1). Hierarchical clustering was used to visualize the calculated distances." We have added a note to the figure legend referring the reader to this part of the Materials and methods section.

> • The model in [Figure 6](#fig6){ref-type="fig"} and several statements throughout the manuscript indicate a complete lack of specific proteins in the nuclear and cytoplasmic complexes. Please clarify if this is an accurate interpretation. Are some proteins enriched in specific complexes and depleted in others rather than absent?

If we understand the reviewer's question correctly, using the split tandem experiment as a model to answer -- only ORF1p was quantitatively shifted at or nearly 100% to the elution fraction of the 2D purification (binary relationship -- it is in one fraction and not in another). Note that, for technical reasons related to quantitation using shotgun proteomics, zero-values for proteins (that may actually not be present) are not recorded in any sample, and small values instead are derived either from noise or imputed. ORF1p was shown to be \~100% in the final elution fraction by western blot (Taylor et al. 2013) and by MS (this study). Other proteins generated much of their signal (as graphed) in the ORF1p containing fraction, but some proportion may have decayed away (remaining in the supernatant) or be partially associated with the ORF2p-only fraction. We cannot distinguish between these scenarios based on that data alone. The inverse is also true for proteins in the supernatant. UPF1 represents a protein that we hypothesize to be specifically present in both complexes because of its borderline behavior in numerous experiments. Being an RNP that evolves from one lifecycle stage to the next, proteins likely exchange on and off the complex dynamically along the way. These proteins may exhibit absolute or conditional dependencies, resulting in heterogeneous mixtures or continua of RNPs. [Figure 3](#fig3){ref-type="fig"} (now [Figure 4](#fig4){ref-type="fig"}) demonstrates varying degrees of coordination of protein associations with L1 based on catalytic mutants. E.g. association with TOP1 seems nearly-dependent on catalytic activity or an activity-associated cellular context. [Figure 4](#fig4){ref-type="fig"} (now [Figure 5](#fig5){ref-type="fig"}) demonstrates varying degrees of coordination in protein decay and exchange from L1s in vitro. Several proteins appear to behave nearly identically, within different classes. However, there are few binary, strictly present/not present, relationships observed across these many experiments. [Figure 5](#fig5){ref-type="fig"} (now [Figure 6](#fig6){ref-type="fig"}) is an attempt to synthesize the sum of the data into a model of co-behavioral patterns that explain the results. [Figure 6](#fig6){ref-type="fig"} (now [Figure 7](#fig7){ref-type="fig"}) is a schematic that reflects our degree of belief, based on the data, of physiologically relevant steady state features of L1. We cannot rule out that some nuclear proteins that are also found in the cytoplasm could join L1s in the cytoplasm (making no assumptions about a given RNP's continued progress in the lifecycle), or the vice versa. We assume that some host factors assembled in the cytoplasm may indeed carry through to the nucleus, perhaps UPF1 is an example, or, perhaps UPF1 joins cytoplasmic and nuclear L1 fractions in distinct binding events with distinct outcomes. Dissecting these relationships in greater resolution is the topic of our ongoing work.

> • Statements that are supported by unpublished data that are not shown in this or the accompanying manuscript should be eliminated or restated.

Done.

> • Discuss the possibility that the lack of detection of the L1 ORF1p in the nucleus by IHC could be due to technical problems rather than the lack of the protein?

This section has been re-written; we do not make a point of not detecting ORF1p in the nucleus in our IF assays anymore, and instead refer to Mita et al. the co-submission that does demonstrate nuclear ORF1p. We understand that this reviewer did not have access to the co-submitted manuscript by Mita et al. -- in its current state the text stands on its own and does not suggest a failure to detect nuclear ORF1p means a lack of ORF1p in the nucleus.

[^1]: These authors contributed equally to this work.
